On this page
Quick Reference
Overview and Recommendations
Background
- •Define cerebral edema as an increase in brain volume resulting from fluid accumulation, which is a secondary response to primary insults such as , (TBI), or metabolic disturbances.
- •Distinguish between cytotoxic edema, which involves intracellular water shift due to Na+/K+-ATPase pump failure (common in early ischemia), and vasogenic edema, which involves (BBB) breakdown allowing protein-rich fluid into the extracellular space (common in tumors and late-stage stroke).
- •Recognize malignant cerebral edema (MCE) as a rapid-onset, life-threatening form of swelling typically following large-vessel occlusions (e.g., middle cerebral artery), carrying a mortality rate exceeding 80% without aggressive intervention.
- •Identify the role of molecular drivers such as the SUR1-TRPM4 cation channel and Aquaporin-4 (AQP4) water channels, which facilitate the movement of water into the brain parenchyma during the acute phase of injury.
- •Understand the clinical significance of the Monro-Kellie doctrine, which states that the sum of volumes of brain, CSF, and intracerebral blood is constant; an increase in one (edema) must be compensated by a decrease in others or ICP will rise exponentially.
Evaluation
- •Suspect cerebral edema in any patient with a sudden decline in Glasgow Coma Scale (GCS) score, new focal neurological deficits, or signs of increased ICP such as worsening headache, nausea, and projectile vomiting.
- •Ask about the temporal progression of symptoms; edema typically peaks between 24 and 72 hours following an acute ischemic or traumatic insult.
- •Examine for the Cushing Triad—hypertension, bradycardia, and irregular respirations—which is a late and ominous sign of impending brainstem herniation.
- •Perform a pupillary exam to check for anisocoria or a fixed, dilated pupil, which suggests uncal herniation and compression of the third cranial nerve.
- •Obtain a non-contrast CT (NCCT) head immediately as the first-line imaging to assess for midline shift, sulcal effacement, and ventricular compression.
- •Measure the Optic Nerve Sheath Diameter (ONSD) using point-of-care ultrasound (POCUS); a diameter > 5.5 mm is highly suggestive of elevated ICP (> 20 mmHg).
- •Order an MRI with Diffusion-Weighted Imaging (DWI) and Apparent Diffusion Coefficient (ADC) maps to differentiate cytotoxic (low ADC) from vasogenic (high ADC) edema.
- •Calculate the Alberta Stroke Program Early CT Score (ASPECTS) in stroke patients; a score of 1–5 or an ischemic core volume > 80 mL indicates a high risk for malignant progression.
- •Monitor serum sodium and osmolality frequently, especially in patients with or those undergoing hyperosmolar therapy, to avoid rapid osmotic shifts.
- •Rule out metabolic mimics and contributors, such as severe hyperammonemia in or rapid glucose drops in (DKA).
Management
- •Elevate the head of the bed to 30 degrees and maintain the neck in a neutral midline position to optimize venous outflow from the cranium.
- •Administer Mannitol 20% at a dose of 0.5 to 1.0 g/kg IV bolus over 15 minutes for acute neurological deterioration; repeat every 4–6 hours as needed while maintaining serum osmolality < 320 mOsm/kg.
- •Utilize Hypertonic Saline (HTS) 3% as an alternative or adjunct, typically given as a 250 mL bolus or 3 mL/kg, targeting a serum sodium of 145–155 mEq/L.
- •Administer Dexamethasone 10 mg IV initially, followed by 4 mg every 6 hours, specifically for vasogenic edema associated with primary or metastatic brain tumors.
- •Avoid corticosteroids in patients with acute ischemic stroke or traumatic brain injury, as they have shown no benefit and may increase the risk of infection and hyperglycemia.
- •Maintain normothermia (37.0°C) aggressively, as fever increases cerebral metabolic demand and exacerbates secondary brain injury.
- •Provide adequate analgesia and sedation (e.g., Propofol infusion 5–50 mcg/kg/min) to reduce sympathetic surges and metabolic rate.
- •Ensure Cerebral Perfusion Pressure (CPP) remains between 60 and 70 mmHg by maintaining adequate mean arterial pressure (MAP) with vasopressors if necessary.
- •Avoid hypotonic fluids such as 0.45% normal saline or D5W, which decrease serum osmolarity and promote water movement into the brain.
- •Refer for urgent Decompressive Hemicraniectomy in patients < 60 years old with malignant MCA syndrome who deteriorate within 48 hours despite medical therapy.
- •Implement brief hyperventilation (target PaCO2 30–35 mmHg) only as a temporary bridge to definitive surgical or osmotic therapy during an acute herniation crisis.
- •Monitor for seizures, which can worsen edema; initiate Levetiracetam 1500 mg IV bolus followed by 500–1500 mg twice daily if clinical or electrographic seizures occur.
- •Consider external ventricular drain (EVD) placement for CSF diversion if interstitial edema from obstructive is present.
- •Limit sodium correction in chronic hyponatremia to < 8–10 mEq/L per 24 hours to prevent osmotic demyelination syndrome.
- •Discharge criteria include stabilized ICP for > 48 hours without hyperosmolar therapy, improving GCS, and radiographic resolution of midline shift.
Board Review — High Yield
- •Cytotoxic Edema — Intracellular swelling due to Na+/K+ pump failure; appears as restricted diffusion (low ADC) on MRI.
- •Vasogenic Edema — Extracellular fluid from BBB breakdown; predominantly involves white matter and is steroid-responsive in oncology.
- •Cushing Triad — Hypertension, bradycardia, and irregular respirations; indicates late-stage increased ICP and impending herniation.
- •Monro-Kellie Doctrine — The rigid skull creates a fixed volume; any increase in brain volume must be offset by decreased CSF or blood.
- •Malignant MCA Syndrome — Rapid swelling after large stroke; decompressive hemicraniectomy within 48 hours reduces mortality in those < 60 years.
- •Optic Nerve Sheath Diameter (ONSD) — Ultrasound measurement > 5.5 mm correlates with ICP > 20 mmHg.
- •Interstitial Edema — Seen in obstructive hydrocephalus; fluid is forced across the ependymal lining into periventricular white matter.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Cerebral edema is a secondary pathological response to injury, peaking typically within **24-72 hours** post-insult [1, 4].
- ▸Malignant Cerebral Edema (MCE) is a high-mortality variant (>80%) requiring rapid identification and intervention [2].
- ▸The classification into cytotoxic, vasogenic, interstitial, and osmotic types is based on the integrity of the blood-brain barrier and the specific fluid compartment involved [10, 14, 27].
Cerebral edema is defined as an abnormal accumulation of fluid within the brain parenchyma that results in an increase in total brain volume and, frequently, a secondary rise in intracranial pressure [2][4][10]D. This pathological state is not a primary disease but a secondary response to various insults, including , (TBI), and metabolic disturbances [1][11]D[14]D. The condition is clinically significant because the rigid confines of the cranium limit expansion; even small increases in volume can lead to brain herniation and death [4].
Synonyms and Alternate Nomenclature
In clinical practice and research literature, several terms are used interchangeably or to describe specific severities of cerebral edema:
- Brain Swelling: Often used in the context of cytotoxic edema following acute ischemic stroke (AIS) [1].
- Malignant Cerebral Edema (MCE): A life-threatening, rapid-onset form of edema typically following large-vessel occlusion, associated with mortality rates exceeding 80% without aggressive intervention [2].
- Encephalic Edema: A general term for parenchymal fluid accumulation.
- Cerebral Congestion: Historically used to describe increased intracranial blood volume, though distinct from true interstitial or intracellular edema.
Phases and Clinical Evolution
The progression of cerebral edema follows a predictable temporal course, which is critical for determining the window for therapeutic intervention.
- Prodromal/Initial Phase: Occurs immediately following the primary insult (e.g., the ictus of a stroke or the moment of impact in TBI). During this phase, molecular triggers such as the upregulation of the SUR1-TRPM4 channel and Aquaporin-4 (AQP4) expression begin [6][10]D.
- Progressive Phase: Characterized by the active accumulation of fluid. In acute intracerebral hemorrhage (ICH) and AIS, this phase typically peaks between 24 and 72 hours [1][3][4].
- Nadir (Clinical Peak): The point of maximal edema volume and highest risk for neurological deterioration. Radiographically, this is often identified by an Apparent Diffusion Coefficient (ADC) threshold below 620 × 10-6 mm²/s in ischemic cores [30]D.
- Plateau Phase: A period of stabilized volume where intracranial pressure (ICP) management is most intensive.
- Recovery/Resolution Phase: The gradual clearance of fluid, increasingly recognized as being mediated by the glymphatic system—a glial-dependent waste clearance pathway that utilizes perivascular spaces to exchange cerebrospinal fluid (CSF) and interstitial fluid [13]D[21]D.
Pathophysiological Classification
Cerebral edema is classified based on the anatomical compartment where fluid accumulates and the status of the (BBB).
Cytotoxic (Cellular) Edema
Cytotoxic edema involves the intracellular accumulation of fluid due to the failure of ATP-dependent ion pumps (e.g., Na+/K+-ATPase). This leads to an influx of sodium and water into neurons, glia, and endothelial cells [10]D[22]D.
- Mechanism: Ischemia triggers the opening of SUR1-TRPM4 cation channels, leading to massive sodium influx and necrotic cell death [6]. AQP4 plays a paradoxical role; it facilitates the initial intracellular water influx in acute ischemia but is also necessary for fluid clearance during later stages [10]D[24]D.
- Key Feature: The BBB remains initially intact, but the shift of fluid from the extracellular to the intracellular space causes cellular swelling [16]C[22]D.
Vasogenic Edema
Vasogenic edema results from the physical disruption of the BBB, allowing plasma proteins and water to leak into the extracellular interstitial space [10]D[27]D.
- Mechanism: Mediated by inflammatory cytokines and growth factors like Vascular Endothelial Growth Factor (VEGF), which downregulate tight junction proteins such as occludin [27]D. In oncology, this is the primary mechanism for edema surrounding glioblastomas, where dexamethasone 4-10 mg every 6 hours is frequently used to stabilize the BBB [9]D[19]D.
- Key Feature: Predominantly involves white matter, as the parallel fiber bundles provide low-resistance pathways for fluid spread [16]C[28]D.
Interstitial (Hydrocephalic) Edema
This type occurs when the transependymal flow of CSF is forced into the brain parenchyma, typically due to obstructive [13]D[28]D.
- Mechanism: Increased intraventricular pressure overcomes the ependymal lining, leading to fluid accumulation in the periventricular white matter [28]D.
Osmotic Edema
Osmotic edema occurs when an abnormal osmotic gradient exists between the blood and the brain tissue [5][14]D.
- Mechanism: In severe (serum sodium ≤120 mEq/L), the relatively higher osmolality of the brain tissue draws water across the BBB [5][8]D. Similarly, in Hepatic Encephalopathy (HE), the accumulation of ammonia leads to increased glutamine within astrocytes, creating an osmotic draw that results in astrocytic swelling [14]D[20]D.
| Type | Primary Location | BBB Integrity | Key Mechanism | Common Etiology |
|---|---|---|---|---|
| Cytotoxic | Intracellular | Intact (Initially) | Na+/K+ pump failure; SUR1-TRPM4 opening [6][10]D | Ischemic stroke, early TBI, toxins [16]C[24]D |
| Vasogenic | Extracellular (White matter) | Disrupted | VEGF-mediated tight junction breakdown [27]D | Brain tumors, abscesses, late-stage trauma [9]D[19]D |
| Interstitial | Periventricular | Intact | Transependymal CSF flow [13]D[28]D | Obstructive hydrocephalus [28]D |
| Osmotic | Generalized | Intact | Plasma hypoosmolality (e.g., hyponatremia) [5][8]D | Hyponatremia, Hepatic Encephalopathy [14]D[20]D |
Epidemiology and Risk Factors
- ▸Malignant cerebral edema occurs in approximately 22.2% of large vessel occlusion strokes, with insular infarction increasing risk (OR 2.93).
- ▸In pediatric DKA, iatrogenic factors such as bicarbonate use and early insulin administration (<1 hour) are critical risk factors for cerebral edema.
- ▸Severe hyponatremia (Na ≤ 125 mmol/L) presents with radiographic or clinical cerebral edema in 37% of emergency department admissions.
Cerebral edema (CE) is not a primary disease but a critical secondary complication of various neurological and metabolic insults. Its epidemiology varies significantly depending on the underlying etiology, with the highest morbidity and mortality observed in cases of malignant cerebral edema (MCE) following large vessel occlusion (LVO) and pediatric diabetic ketoacidosis (DKA) [41][52]D.
Incidence and Prevalence Across Primary Insults
The prevalence of cerebral edema is most rigorously documented in the context of acute ischemic stroke (AIS). In patients with anterior circulation LVO, MCE occurs in approximately 22.2% of cases [52]D. Even after successful mechanical thrombectomy (MT), the "no-reflow phenomenon"—persistent microvascular impairment despite large vessel recanalization—occurs in 3.3% to 63% of patients, contributing to secondary edema and poor outcomes [50]D.
In the context of aneurysmal subarachnoid hemorrhage (aSAH), early cerebral edema (ECE) is a hallmark of early brain injury, occurring within the first 72 hours of ictus [44]. For metabolic derangements, severe hyponatremia (plasma sodium ≤ 125 mmol/L) is associated with a CE incidence of 37% at the time of emergency department presentation [57]D. Traumatic brain injury (TBI) remains the leading cause of death in individuals aged 18-44, with cerebral edema and intracranial hemorrhage serving as the primary life-threatening acute complications [51]D.
Risk Factors for Malignant Cerebral Edema (MCE)
MCE is a devastating form of edema characterized by rapid brain swelling and herniation. Identifying patients at risk is crucial for proactive management, such as early decompressive hemicraniectomy [38].
- Neuroanatomical Factors: Infarction involving the insular cortex is a potent predictor of MCE. Insular involvement synergistically amplifies risk when combined with low Alberta Stroke Program Early CT Scores (ASPECTS) and high National Institutes of Health Stroke Scale (NIHSS) scores, carrying an odds ratio (OR) of 2.93 [52]D.
- Molecular Mechanisms: The upregulation of the SUR1-TRPM4 channel in neurovascular units is a key driver of ionic edema and necrotic cell death following ischemic stroke [6][35]. Sulfonylureas, which inhibit this channel, are under investigation for their potential to mitigate this risk [31][34].
- Procedural Risks: In patients undergoing endovascular thrombectomy, risk factors for requiring post-procedural decompressive craniectomy include high baseline NIHSS and poor collateral circulation [36]. Postoperative CE is also a recognized complication of meningioma resection and stereotactic brain biopsies, though infection-related edema in the latter is rare [39][40].
Pediatric and Metabolic Vulnerabilities
Pediatric populations face unique risks, particularly regarding DKA and abusive head trauma (AHT). DKA is the leading cause of mortality in pediatric diabetes, primarily due to CE [41].
- DKA Management Risks: Iatrogenic factors significantly influence CE risk in children. The use of bicarbonate for acidosis correction and the administration of insulin within the first hour of fluid resuscitation are established risk factors for the development of CE [41]. While balanced electrolyte solutions (BES) are often compared to normal saline (0.9% NS) to reduce hyperchloremic acidosis, the primary risk for CE remains the speed and timing of metabolic correction [32].
- Abusive Head Trauma: In children younger than 36 months with confirmed AHT, intracranial hemorrhage is present in 87.6% of cases, frequently accompanied by retinal hemorrhages (63.5%) and subsequent diffuse cerebral edema [42].
Risk Stratification Protocol for Malignant Cerebral Edema
Clinicians should follow a systematic approach to identify high-risk patients following an ischemic insult to initiate proactive monitoring.
- Step 1: Identify Primary Insult Severity → Assess NIHSS score at presentation; scores > 15-20 indicate a high risk for MCE [52]D.
- Step 2: Radiographic Mapping → Evaluate ASPECTS on non-contrast CT. Specifically, check for insular cortex involvement and midline shift [31][52]D.
- Step 3: Assess Recanalization Status → In patients post-MT, monitor for the no-reflow phenomenon and successful TICI (Thrombolysis in Cerebral Infarction) grading [50]D.
- Step 4: Continuous Monitoring → Implement frequent neurological checks and consider AI-based radiomic tools to predict edema progression [38][45].
| Risk Factor | Population | Association (OR/RR) | Evidence Level |
|---|---|---|---|
| Insular Infarction | Acute Ischemic Stroke | OR 2.93 | Level 5 [52]D |
| Early Insulin (<1 hr) | Pediatric DKA | High Risk | Level 1c [41] |
| Bicarbonate Use | Pediatric DKA | High Risk | Level 1c [41] |
| Severe Hyponatremia | General ED | 37% Incidence | Level 5 [57]D |
| No-Reflow Phenomenon | Post-Thrombectomy | 3.3% - 63% Prevalence | Level 5 [50]D |
| Abusive Head Trauma | Children <36 months | 87.6% ICH Prevalence | Level 2b [42] |
Etiology and Triggering Factors
- ▸Malignant cerebral edema is a life-threatening complication of large-vessel ischemic stroke (MCA/ICA occlusion) that can lead to death in 80% of untreated cases [61].
- ▸Bacterial meningitis induces edema via a cytokine storm (IL-1β, TNF-α) triggered by TLR and NLRP3 activation [64].
- ▸Acute hyponatremia (sodium ≤120 mEq/L) causes rapid osmotic cellular swelling, requiring urgent but controlled correction [5, 65].
Cerebral edema is primarily caused by the disruption of the (BBB) or osmotic imbalances that lead to the abnormal accumulation of fluid within the brain parenchyma [64]D[65]D. This pathological state is rarely a primary condition but rather a secondary manifestation of diverse mechanical, vascular, infectious, or metabolic insults that compromise the integrity of the (NVU) [50]D[63]D.
Vascular and Ischemic Triggers
Ischemic events are among the most frequent causes of cerebral edema, particularly malignant cerebral edema (MCE), which occurs following large-volume ischemic strokes, such as those involving the middle cerebral artery (MCA) or internal carotid artery (ICA) [45][61]D. The mechanism involves a transition from cytotoxic edema (cellular swelling) to vasogenic edema as the BBB breaks down. Even after successful mechanical thrombectomy, patients may experience the no-reflow phenomenon (NRP), where microvascular tissue reperfusion remains impaired due to intraluminal occlusion and extraluminal constriction [50]D. This NRP is driven by inflammatory responses and abnormal interactions within the NVU, significantly increasing the risk of poor outcomes [50]D.
In pediatric populations, stroke-induced edema can arise from ischemic, hemorrhagic, or venous-thrombotic events, often presenting with seizures more frequently than in adults [66]D. Furthermore, subarachnoid hemorrhage (SAH) triggers edema through the activation of astrocytic aquaporin-4 (AQP4), which drives water movement into the brain while paradoxically impairing the 's ability to clear macromolecules [77]D.
Traumatic and Mechanical Insults
(TBI) initiates a complex cascade of secondary injuries that exacerbate cerebral edema. The initial physical damage triggers cerebrovascular unit (CVU) activation, leading to endothelial dysfunction, hypoxia, and a robust inflammatory response [62]D[63]D.
Pathogenic Sequence of TBI-Induced Edema:
- Primary Insult: Direct mechanical tissue damage and CVU activation [63]D.
- Secondary Cascade: Release of inflammatory mediators and oxidative stress, specifically involving NOX4-mediated pathways [70]D[78]D.
- BBB Disruption: Astrocyte activation and microglia polarization (M1 phenotype) increase vascular permeability [68]D[82]D.
- Metabolic Failure: Disruption of epigenetic homeostasis and bioenergetic collapse [62]D[71]D.
Infectious and Inflammatory Causes
Bacterial meningitis, particularly streptococcal infections, causes devastating edema through dysregulated immune responses. Pathogens are recognized by microglial TLRs and NLRP3 inflammasomes, triggering a "cytokine storm" characterized by elevated IL-1β and TNF-α [64]D. This inflammatory surge leads to neutrophil infiltration and massive BBB disruption [64]D.
Autoimmune triggers, though rarer, include Neuropsychiatric Lupus (NPSLE). In severe cases, NPSLE can present with acute coma and nonspecific cerebral edema on imaging, often associated with significant vascular compromise and systemic inflammation [67]C.
Metabolic and Environmental Triggers
Hyponatremia is the most common electrolyte disorder leading to cerebral edema in hospitalized patients [65]D. When serum sodium levels drop rapidly, often to ≤120 mEq/L, an osmotic gradient is created that forces water into the relatively hypertonic brain cells [5][65]D.
High-Altitude Cerebral Edema (HACE) is a lethal environmental emergency occurring at extreme elevations. The mechanism involves pathological rewiring of cell-type interactions, impaired energy metabolism, and loss of BBB integrity due to severe hypoxia [69]D.
Neoplastic and Treatment-Induced Factors
Primary brain tumors like glioblastoma (GBM) and metastatic lesions (e.g., from non-small-cell lung cancer) induce peri-tumoral edema by secreting vascular endothelial growth factor (VEGF) and disrupting the glymphatic system [28]D[60]. Glioma growth can occlude inflow and outflow pathways of the glymphatic system, preventing the clearance of solutes and fluid [28]D. Interestingly, therapeutic interventions such as photodynamic therapy (PDT) for GBM, while improving local tumor control, can acutely alter the local inflammatory environment and fluid dynamics [59].
| Cause | Category | Mechanism | Associated Subtype | Key Reference |
|---|---|---|---|---|
| Large-core Infarction | Vascular | Bioenergetic failure & NVU disruption | Malignant Cerebral Edema (MCE) | [45][61]D[73]D |
| Traumatic Brain Injury | Traumatic | Endothelial dysfunction & M1 microglia polarization | Secondary Brain Injury | [62]D[63]D[82]D |
| Bacterial Meningitis | Infectious | TLR/NLRP3-mediated cytokine storm | Streptococcal Meningitis | [64]D |
| Hyponatremia | Metabolic | Osmotic water shift (Sodium ≤120 mEq/L) | Acute Hyponatremia | [5][65]D |
| Glioblastoma | Neoplastic | VEGF secretion & glymphatic occlusion | Peri-tumoral Edema | [28]D[59] |
| High Altitude | Environmental | Hypoxia-induced BBB breakdown | HACE | [69]D |
| NPSLE | Autoimmune | Systemic vascular compromise | Neuropsychiatric Lupus | [67]C |
Pathophysiology of Cerebral Edema
- ▸Cerebral edema progresses from an early cytotoxic phase (intracellular swelling via Na+/K+ pump failure) to a later vasogenic phase (BBB breakdown via tight junction degradation).
- ▸Aquaporin-4 (AQP4) plays a paradoxical role, facilitating water influx during the formation of cytotoxic edema but aiding in fluid clearance during the resolution of vasogenic edema.
- ▸The loss of AQP4 polarization on astrocyte endfeet is a hallmark of glymphatic system dysfunction, which impairs the clearance of interstitial fluid and exacerbates tissue swelling.
The development of cerebral edema is a complex, multi-phasic process involving the failure of cellular ion homeostasis, the structural breakdown of the blood-brain barrier (BBB), and the impairment of the brain's specialized fluid clearance pathways. While traditionally categorized into cytotoxic and vasogenic types, contemporary understanding emphasizes a continuum where molecular triggers—ranging from hypoxia to inflammatory cytokines—converge on common pathways of tissue swelling [10]D[84]D.
The Cytotoxic Phase: Cellular Ion Failure
Cytotoxic edema, or cellular swelling, is the earliest phase of edema, occurring within minutes of an insult such as ischemic stroke or traumatic brain injury (TBI) [10]D[11]D.
Step 1: Energy Failure → Step 2: Ion Pump Dysfunction → Step 3: Osmotic Influx → Step 4: Cellular Swelling
In ischemic conditions, the depletion of adenosine triphosphate (ATP) leads to the failure of energy-dependent ion pumps, primarily the Na+/K+-ATPase [79]D. This results in the intracellular accumulation of sodium (Na+) and the loss of potassium (K+). The resulting osmotic gradient drives the influx of water from the extracellular space into the intracellular compartment, primarily through Aquaporin-4 (AQP4) water channels [10]D. AQP4 is the most abundant water channel in the central nervous system, localized predominantly on the endfeet of astrocytes [10]D[29]D. During the acute phase of ischemia, AQP4 facilitates the rapid entry of water into astrocytes, exacerbating cytotoxic swelling [10]D.
The Vasogenic Phase: Blood-Brain Barrier Disruption
Vasogenic edema involves the physical breakdown of the BBB, allowing the extravasation of plasma proteins and fluid into the interstitial space [83]D[93]D. This process is driven by several molecular mechanisms:
- Tight Junction Degradation: Pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 activate matrix metalloproteinases (MMPs), particularly MMP-9, which degrade tight junction proteins like Claudin-5 and Occludin [64]D[79]D[88]D.
- Endothelial Injury: In stroke, brain microvascular endothelial cells (BMECs) undergo ferroptosis, an iron-dependent form of lipid peroxidation-driven cell death that compromises structural integrity [7]D. Similarly, in cerebral malaria, the sequestration of infected erythrocytes leads to local hypoxemia and endothelial activation [12]D.
- Inflammatory Signaling: The release of CCL2 (C-C Motif Chemokine Ligand 2) and its interaction with the CCR2/NF-κB pathway further increases BBB permeability, particularly in secondary injury following intracerebral hemorrhage (ICH) [85]D[92]D.
- Novel Mediators: Recent evidence identifies soluble ST2 (sST2), an immune regulator produced by brain endothelial cells, as a key mediator that correlates with the severity of edema following large ischemic strokes [87]D.
Glymphatic System Dysfunction and AQP4 Polarization
The glymphatic system is a macroscopic waste clearance system that utilizes perivascular channels to facilitate the flow of cerebrospinal fluid (CSF) and interstitial fluid (ISF) [11]D[74]D.
Mechanism of Glymphatic Failure:
- Loss of AQP4 Polarization: In healthy tissue, AQP4 is highly polarized to the astrocyte endfeet facing the vasculature. Following TBI or stroke, this polarization is lost, and AQP4 redistributes across the entire astrocyte cell body [74]D[100]D.
- Impaired Clearance: The loss of polarization disrupts the convective flow of fluid, leading to the accumulation of metabolic waste and water in the parenchyma [11]D[86]D.
- TRPV4 Involvement: The TRPV4 (Transient Receptor Potential Vanilloid 4) channel has been implicated in modulating AQP4 polarization; targeting TRPV4 may restore glymphatic function and alleviate edema [100]D.
Etiology-Specific Pathophysiology
Different triggers utilize distinct molecular pathways to arrive at cerebral edema:
- Bacterial Meningitis: Pathogens are recognized by microglial TLRs and the NLRP3 inflammasome, triggering a "cytokine storm" that drives massive BBB disruption [64]D.
- High-Altitude Cerebral Edema (HACE): Prolonged hypobaric hypoxia induces the autophagic degradation of Claudin-5 in endothelial cells, leading to rapid vasogenic leakage [88]D.
- Cerebral Malaria: Beyond endothelial activation, cuproptosis (copper-dependent programmed cell death) in astrocytes has been identified as a driver of BBB instability [91]D.
- Traumatic Brain Injury (TBI): Mechanical shear forces cause immediate vascular disruption, followed by a secondary wave of injury mediated by Neutrophil Extracellular Traps (NETs), which induce further endothelial damage and vasospasm [11]D[96]D.
| Mediator | Source | Mechanism of Action | Clinical Context |
|---|---|---|---|
| MMP-9 | Neutrophils, Microglia | Degradation of Claudin-5 and Occludin [79]D | Ischemic Stroke, TBI |
| TNF-α | Microglia, Macrophages | Activation of inflammatory cascades and endothelial apoptosis [12]D[64]D | Meningitis, Malaria |
| CCL2 | Astrocytes, Endothelium | CCR2/NF-κB mediated tight junction disruption [85]D | ICH, High-Altitude Edema |
| sST2 | BMECs | Candidate mediator of vascular permeability [87]D | Large Vessel Occlusion |
| NETs | Neutrophils | Direct endothelial toxicity and microvascular thrombosis [96]D | TBI, Sepsis |
History and Physical Examination
- ▸Cerebral edema symptoms often peak between 24 and 72 hours in acute stroke, with a midline shift of ≥ 5 mm serving as a critical radiographic threshold for malignant progression.
- ▸Optic nerve sheath diameter (ONSD) measurement > 5.5 mm is a validated, non-invasive bedside marker for elevated intracranial pressure.
- ▸Amyloid-related imaging abnormalities (ARIA-E) are a distinct phenotypic variant occurring in up to 24% of patients receiving anti-amyloid monoclonal antibodies.
The clinical presentation of is a dynamic process that reflects the brain's limited capacity for expansion within the rigid cranium. Symptoms typically progress over hours to days, depending on the underlying etiology, such as traumatic brain injury (TBI), large hemispheric infarction (LHI), or metabolic derangements [106][120]D. In cases of malignant brain edema (MBE) following stroke, neurological deterioration often correlates with a midline shift ≥ 5 mm [106].
Presenting Symptoms
Patients with cerebral edema often present with signs of increased (ICP). The classic triad of headache, nausea, and vomiting results from the stretching of pain-sensitive dural structures and pressure on the medullary emetic centers [104].
- Headache: Often described as worse in the morning or when performing a Valsalva maneuver, which further impairs venous drainage.
- Altered Consciousness: This ranges from mild confusion and lethargy to deep coma. In (ALF), hepatic encephalopathy is a primary driver of altered mental status, which may progress to fatal cerebral herniation [124]D[127]D.
- Visual Disturbances: Patients may report blurred vision or diplopia, often due to pressure on the cranial nerves or the development of papilledema [111]C.
Neurological Examination Findings
A systematic neurological examination is essential to localize the edema and assess the risk of herniation.
Cranial Nerve and Ocular Assessment
Papilledema is a hallmark of chronic or subacute ICP elevation, though it may be absent in hyperacute settings. A critical non-invasive bedside tool is the measurement of the Optic Nerve Sheath Diameter (ONSD) using point-of-care ultrasound (POCUS) [108][122]D. The optic nerve is encased in a continuation of the subarachnoid space; thus, elevated ICP causes the sheath to distend [108].
Protocol: Bedside ONSD Measurement [108][122]D
- Step 1: Place a high-frequency linear transducer over the closed eyelid using a thick layer of ultrasound gel to avoid ocular pressure.
- Step 2: Identify the optic nerve as a hypoechoic linear structure posterior to the globe.
- Step 3: Measure the diameter 3 mm posterior to the globe.
- Step 4: Compare transverse and sagittal axes; a diameter > 5.0–5.5 mm is highly suggestive of elevated ICP [122]D.
Motor and Reflex Examination
Cerebral edema can manifest as focal deficits or generalized motor dysfunction. In patients with large strokes, the development of MBE is associated with worsening hemiparesis and the emergence of spasticity [115]. Rare presentations, such as those following CAR-T therapy (ICANS), can manifest as acute quadriparesis or paraparesis [112]C.
Autonomic and Vital Sign Monitoring
The Cushing Triad (hypertension, bradycardia, and irregular respirations) is a late and ominous sign of impending brainstem herniation. Recent evidence also suggests that decreased 24-hour parasympathetic activity, measured via heart rate variability (HRV), is a significant predictor of perihematomal edema (PHE) expansion and poor functional outcomes in [117]D.
Phenotypic Variants
Cerebral edema presents differently depending on the clinical context. The table below summarizes key variants encountered in modern practice.
| Variant | Key Features | Frequency/Context |
|---|---|---|
| ARIA-E | Vasogenic edema/effusions associated with anti-amyloid therapies (e.g., donanemab, lecanemab) [101][110]C. | 15.6%–24.2% in clinical trials [101]. |
| HACE | High-altitude cerebral edema; characterized by ataxia, altered consciousness, and severe headache [104][125]D. | Occurs at altitudes > 2500 m [104]. |
| PRES | Posterior reversible encephalopathy syndrome; typically involves parieto-occipital vasogenic edema [53]D[121]D. | Associated with hypertension, eclampsia, or immunosuppression [53]D. |
| ICANS | Immune effector cell-associated neurotoxicity syndrome; presents with encephalopathy and seizures after CAR-T therapy [112]C. | Common in CD19- or CD22-directed therapies [112]C. |
Red Flags
Clinicians must remain vigilant for signs of rapid neurological decline that necessitate urgent intervention:
- Pupillary Changes: A fixed, dilated pupil (unilateral) suggests uncal herniation and compression of the third cranial nerve.
- Respiratory Compromise: Cheyne-Stokes respirations or central neurogenic hyperventilation indicate brainstem involvement.
- Seizures: Edema is a significant prognostic factor for seizures, particularly in patients with meningiomas or those undergoing stereo-electroencephalography (SEEG) [105][113][118]D.
Atypical Presentations
- Infants: In young infants (≤ 6 months), cerebral edema may present as sepsis-like illness or clinical seizures, often associated with parechovirus (HPeV) infection [107].
- Atypical PRES: While classic PRES is posterior, atypical variants can involve the brainstem, cerebellum, or deep gray nuclei, complicating the diagnosis [121]D.
- Metabolic Mimics: Wernicke encephalopathy can mimic the edematous white matter lesions seen in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) [109]C.
| Variant | Key Features | Frequency/Context |
|---|---|---|
| ARIA-E | Vasogenic edema/effusions associated with anti-amyloid therapies [101][110]C. | 15.6%–24.2% in clinical trials [101]. |
| HACE | High-altitude cerebral edema; ataxia, altered consciousness [104][125]D. | Altitudes > 2500 m [104]. |
| PRES | Posterior reversible encephalopathy syndrome; parieto-occipital vasogenic edema [53]D[121]D. | Hypertension, eclampsia [53]D. |
| ICANS | Immune effector cell-associated neurotoxicity syndrome; encephalopathy, seizures [112]C. | CD19- or CD22-directed CAR-T [112]C. |
Diagnosis and Workup
- ▸MRI with DWI/ADC is the definitive modality for distinguishing cytotoxic (low ADC) from vasogenic (high ADC) edema.
- ▸A midline shift (MLS) of ≥ 10 mm within 24 hours of injury or intervention is a critical threshold for malignant progression.
- ▸Non-invasive monitoring via Optic Nerve Sheath Diameter (ONSD) ultrasound is a reliable bedside surrogate for intracranial pressure.
The diagnosis of cerebral edema requires a synthesis of clinical neurological assessment, advanced neuroimaging, and, in critical cases, invasive physiological monitoring. Early identification is paramount, as complications such as malignant cerebral edema (MCE) or midline shift (MLS) ≥ 10 mm within the first 24 hours represent life-threatening emergencies requiring immediate surgical or medical intervention [38][80]D.
Diagnostic Criteria
Cerebral edema is primarily a radiological diagnosis supported by clinical evidence of increased intracranial pressure (ICP). Formal criteria include:
- Required Features: Evidence of increased brain volume on imaging (e.g., sulcal effacement, ventricular compression, or midline shift) [135]D[80]D.
- Supportive Features: Clinical signs of intracranial hypertension (headache, nausea, papilledema, or declining GCS) and specific laboratory markers such as elevated anti-GFAP antibodies in autoimmune cases [134]C.
- Exclusion Criteria: Primary hydrocephalus without parenchymal swelling or acute intracranial hemorrhage without associated perihematomal edema (PHE) [129].
Imaging Modalities
Computed Tomography (CT)
Non-contrast CT (NCCT) is the first-line modality due to its speed and ability to detect acute mass effect. A key quantitative marker is the mean Hounsfield Unit (mHU) of perihematomal edema; lower mHU values indicate greater hypodensity and correlate with worse clinical outcomes in intracerebral hemorrhage (ICH) [129]. In patients with acute liver failure (ALF), CT is used to screen for cerebral edema, which occurs in approximately 11.5% of cases and significantly increases the risk of tonsillar herniation [131]. Deep learning models (e.g., 3D U-net) are increasingly utilized for automated segmentation of ICH and PHO to improve diagnostic precision [140]D.
Magnetic Resonance Imaging (MRI)
MRI is the gold standard for differentiating edema types. Diffusion-weighted imaging (DWI) and Apparent Diffusion Coefficient (ADC) maps are essential for distinguishing cytotoxic from vasogenic edema [16]C.
- Cytotoxic Edema: Characterized by restricted diffusion (low ADC). In ischemic stroke, an ADC threshold of 620 × 10⁻⁶ mm²/s is used to delineate the ischemic core [30]D.
- Vasogenic Edema: Characterized by increased diffusion (high ADC) and T2/FLAIR hyperintensity. This pattern is typical in peritumoral brain edema (PTBE) associated with meningiomas [141]D[147]D.
Advanced techniques like Free Water Imaging (FWI) and Neurite Orientation Dispersion and Density Imaging (NODDI) are required to resolve fiber tractography in edematous regions, as standard diffusion tensor imaging (DTI) is often obscured by increased isotropic diffusion [132]D[148]D.
Laboratory and Molecular Workup
Specific laboratory tests are guided by the suspected etiology:
- Genetic Markers: The APOE ε4 genotype is associated with larger PHE volumes due to increased blood-brain barrier disruption [130].
- Autoimmune Markers: Anti-GFAP antibodies in serum or CSF are diagnostic for autoimmune GFAP astrocytopathy presenting with diffuse edema [134]C.
- Toxicology: Serum and urine screening for opioids is critical in pediatric cases to identify POUNCE syndrome (Pediatric Opioid Use-Associated Neurotoxicity with Cerebellar Edema) [144]C. Mercury levels should be checked in cases of symmetrical parenchymal alterations and hypoperfusion [137]C.
Physiological and Bedside Monitoring
Invasive ICP monitoring (e.g., ventricular catheters) remains the gold standard but carries risks of infection and hemorrhage [119]D. Consequently, non-invasive alternatives are prioritized in specific populations:
- Optic Nerve Sheath Diameter (ONSD): Ultrasound measurement of ONSD is a validated surrogate for ICP. It is particularly useful for real-time, bedside monitoring in traumatic brain injury (TBI) and cerebral edema [135]D[136]D.
- Multimodal Monitoring in ALF: In pediatric hepatic failure, invasive monitoring is increasingly discouraged in favor of non-invasive multimodal assessments due to the risk of coagulopathy [20]D.
Diagnostic Algorithm
- Step 1: Clinical Suspicion: Identify signs of increased ICP or focal deficits in high-risk patients (e.g., post-stroke, post-DBS surgery, or ALF) [133]D[131].
- Step 2: Hyperacute Imaging: Perform NCCT to assess for midline shift ≥ 10 mm or acute hemorrhage [80]D[135]D.
- Step 3: Characterization: Utilize MRI (DWI/ADC) to determine if the edema is vasogenic (e.g., peritumoral) or cytotoxic (e.g., ischemic) [16]C[30]D.
- Step 4: Targeted Workup: Order specific labs (APOE, anti-GFAP, or toxicology) based on imaging patterns [130][134]C[144]C.
- Step 5: Continuous Monitoring: Initiate ONSD ultrasound or invasive ICP monitoring if the patient is at risk for herniation [136]D.
| Test | Finding | Timing | Clinical Significance |
|---|---|---|---|
| NCCT | Hypodensity (low mHU), MLS ≥ 10 mm | Hyperacute (<24h) | Predicts MCE and herniation risk [129][80]D |
| MRI DWI/ADC | Restricted diffusion (ADC < 620) | Acute (hours to days) | Delineates ischemic core/cytotoxic edema [30]D |
| US ONSD | Increased diameter | Real-time | Non-invasive surrogate for elevated ICP [136]D |
| Anti-GFAP | Antibody positivity (Serum/CSF) | Subacute | Diagnostic for autoimmune astrocytopathy [134]C |
| APOE Genotype | ε4 Allele presence | Baseline | Predicts increased perihematomal edema [130] |
Diagnosis of Cerebral Edema
- ▸Cerebral edema is a clinico-radiological diagnosis requiring both symptoms of increased ICP and characteristic findings on CT or MRI.
- ▸MRI with DWI and ADC mapping is the gold standard for differentiating vasogenic edema from cytotoxic edema, which is essential for determining the underlying cause.
- ▸Specific anatomical patterns on imaging, such as the parieto-occipital distribution in PRES or the thalamic involvement in ANE, guide the diagnostic workup.
The diagnosis of cerebral edema is a multi-modal process that integrates clinical neurological assessment, advanced neuroimaging, and targeted laboratory investigations to identify both the presence of brain swelling and its underlying pathophysiological mechanism. Early recognition is critical, as cerebral edema can lead to rapid clinical deterioration, coma, and death [160]C[164]C.
Diagnostic Criteria
Formal diagnosis requires the presence of characteristic clinical features supported by objective radiological evidence of increased brain volume or interstitial fluid.
Required Features:
- Radiological Evidence: Symmetrical or focal white matter abnormalities on CT or MRI, typically manifesting as areas of low attenuation (CT) or T2/FLAIR hyperintensity (MRI) [166]D.
- Clinical Correlation: Symptoms of increased intracranial pressure (ICP), including headache, nausea, vomiting, and altered consciousness [150]C[166]D.
Supportive Features:
- Papilledema: Observed on funduscopic examination, indicating transmitted pressure to the optic nerve sheath [151]C[154]D.
- Seizure Activity: Common in specific syndromes like (PRES) and eclampsia [155]D[166]D.
- Focal Neurological Deficits: Depending on the location of the edema (e.g., motor weakness in Systemic Lupus Erythematosus -related leukoencephalopathy) [151]C[163]C.
Exclusion Criteria:
- Primary demyelinating disorders (unless presenting as acute variants like AHLE) [158]C.
- Chronic leukodystrophies (e.g., MLC), which present with chronic rather than acute brain swelling [168]D[174]D.
Laboratory Tests
Laboratory evaluation is essential to differentiate between metabolic, autoimmune, and infectious etiologies of edema.
- Autoimmune Panel: In cases of subacute intracranial hypertension, clinicians must order ANA, anti-DNA, and anti-ENA antibodies to evaluate for Systemic Lupus Erythematosus (SLE) [151]C. Notably, pediatric SLE may occasionally present as ANA-negative, requiring high clinical suspicion [163]C.
- Metabolic Markers: For suspected metabolite repair disorders like PEBEL2 (NAXD deficiency), elevated serum or CSF lactate levels are characteristic [159]C.
- Infectious Workup: Blood and CSF cultures are mandatory if acute necrotizing encephalopathy (ANE) is suspected, as bacterial triggers like E. coli can induce a hyperinflammatory state leading to diffuse edema [160]C. In endemic areas, peripheral blood smears for Plasmodium falciparum are necessary to rule out cerebral malaria, where cytoadherence of "sticky" red blood cells causes microvascular clogging and subsequent edema [153]D.
- Inflammatory Cytokines: Emerging research suggests that serum CCL4 levels may help differentiate central nervous system inflammatory diseases from gliomas [171]D.
Imaging
Neuroimaging is the cornerstone of diagnosis, with (MRI) being the modality of choice due to its superior sensitivity in characterizing edema types.
- Computed Tomography (CT): Often the initial test in the emergency setting to rule out mass effect or hemorrhage. Findings include diffuse swelling, loss of sulcal patterns, and effacement of the basal cisterns [151]C[164]C. However, CT may appear indistinguishable between infectious cerebritis and thermal injury-induced vasogenic edema [145]C.
- MRI T2-FLAIR: This sequence is highly sensitive for detecting the hyperintense signal of vasogenic edema, particularly in the posterior parieto-occipital regions characteristic of PRES [150]C[166]D.
- Diffusion-Weighted Imaging (DWI) and ADC Maps: These are critical for differentiating vasogenic edema (increased ADC) from cytotoxic edema (restricted diffusion/decreased ADC) [149][166]D. For example, CHANTER syndrome presents with restricted diffusion specifically in the cerebellum, hippocampus, and basal nuclei [161]C.
- Amyloid-Related Imaging Abnormalities (ARIA): In patients receiving monoclonal antibodies for Alzheimer's, MRI is used to detect ARIA-E (edema/effusion), which manifests as sulcal effusions or parenchymal vasogenic edema [173]C.
Electrodiagnostic Studies
While not primary diagnostic tools for edema itself, electrodiagnostic studies are vital for managing complications:
- Electroencephalography (EEG): Indicated for patients with altered mentation or suspected non-convulsive status epilepticus, which frequently complicates PRES, eclampsia, and ANE [155]D[160]C[166]D.
Diagnostic Algorithm
The following protocol should be initiated upon clinical suspicion of cerebral edema:
- Step 1: Clinical Stabilization and Screening: Perform a rapid neurological exam (GCS, pupils) and funduscopy to check for papilledema [154]D. Assess for systemic triggers like severe hypertension or pregnancy (eclampsia) [155]D[166]D.
- Step 2: Emergent Non-Contrast CT: Rule out immediate life-threatening conditions such as large-volume hemorrhage, obstructive hydrocephalus, or impending herniation [151]C[167]C.
- Step 3: Comprehensive MRI with DWI/ADC: Characterize the pattern of edema. Parieto-occipital involvement suggests PRES [150]C; bilateral thalamic involvement suggests ANE [160]C[164]C; cerebellar and hippocampal involvement suggests CHANTER syndrome [161]C.
- Step 4: Targeted Etiological Workup: Based on the MRI pattern, order specific labs (e.g., toxicology for CHANTER, autoimmune markers for SLE, or blood cultures for ANE) [151]C[160]C[161]C.
| Test | Expected Finding | Timing | Sensitivity | Specificity |
|---|---|---|---|---|
| MRI (DWI/ADC) | Increased ADC (Vasogenic) vs. Decreased ADC (Cytotoxic) | Acute phase | High [166]D | High [149] |
| CT Head | Sulcal effacement, low-density white matter | Emergent | Moderate | Low |
| Funduscopy | Papilledema (optic disc swelling) | Variable | Moderate [154]D | High |
| ANA/Anti-DNA | Positive titers (SLE-related edema) | Subacute | High [151]C | High |
| CSF Lactate | Elevated levels (PEBEL2/NAXD deficiency) | Acute/Febrile | Moderate [159]C | Moderate |
Medical Management
- ▸Hyperosmolar therapy with mannitol (1 g/kg) or hypertonic saline (3 mL/kg bolus) is the primary intervention for acute intracranial hypertension.
- ▸Corticosteroids are highly effective for vasogenic edema in oncology but must be used judiciously in other contexts like ASEM.
- ▸A serum sodium response of < 5 mEq/L after HTS bolus identifies non-responders who may require alternative strategies.
The medical management of is a time-critical endeavor focused on reducing (ICP), maintaining cerebral perfusion, and preventing secondary brain injury. Management strategies vary significantly based on the underlying etiology—whether vasogenic, cytotoxic, or interstitial—and require a tiered approach ranging from hyperosmolar therapy to targeted immunomodulation [3][9]D[176].
Step 1: Initial Assessment and Severity Classification
Immediate management begins with stabilizing the airway, breathing, and circulation while simultaneously assessing the severity of neurological compromise. Clinicians must classify the edema based on clinical and radiographic criteria to determine the appropriate level of care (ICU vs. ward). Key thresholds for aggressive intervention include a Glasgow Coma Scale (GCS) score ≤ 8, which often necessitates invasive monitoring or external ventricular drainage (EVD) [183]D. Radiographic evidence of a midline shift > 0.5 cm or the presence of significant perilesional edema (PLE) in metastatic disease are critical indicators of impending herniation [176][178]. In pediatric populations, early identification of syndromes like acute shock with encephalopathy and multiorgan failure (ASEM) is vital, as these can progress to diffuse edema within hours [184]C.
Step 2: Hyperosmolar Therapy
Hyperosmolar agents are the first-line medical intervention to rapidly reduce brain volume by creating an osmotic gradient that draws water from the brain parenchyma into the intravascular space [3][176].
- Mannitol Protocol: Administer 1 g/kg of 10% mannitol as a single IV infusion at a rate of 10 mL/min [3]. Alternatively, 20% mannitol at 0.6 g/kg may be used for brain relaxation during surgery [176]. Mannitol acts as both an osmotic diuretic and a free radical scavenger, though its efficacy in acute intracerebral hemorrhage (ICH) is still under investigation in trials like MACE-ICH [3][4].
- Hypertonic Saline (HTS) Protocol: Administer a 3 mL/kg bolus of 3% NaCl or a continuous infusion at 20 mL/h [176]. HTS is often preferred in patients with systemic hypotension or those who are non-responsive to mannitol. A "non-responder" to HTS is defined as a patient who fails to achieve a serum sodium increase of ≥ 5 mEq/L within 8 hours of a bolus [43].
Step 3: Targeted Pharmacotherapy and Immunomodulation
Once the acute ICP crisis is stabilized, treatment must address the specific pathophysiology of the edema.
- Vasogenic Edema (Oncology): Glucocorticoids, specifically dexamethasone, are the cornerstone for reducing edema associated with solid tumors and metastases [9]D. They function by restoring the integrity of the (BBB). In cases of non-squamous non-small-cell lung cancer (NSCLC) with brain metastases, the addition of bevacizumab (an anti-VEGF monoclonal antibody) to chemotherapy has shown intracranial efficacy [60].
- Inflammatory/Infectious Edema: In para-infectious syndromes like ASEM, methylprednisolone pulse therapy should be initiated early (e.g., within 200 minutes of presentation) to combat the cytokine storm [184]C. For rare infections like Mycobacterium chelonae following cosmetic procedures, aggressive IV antibiotics are required alongside seizure prophylaxis [185]C.
Step 4: Monitoring and Metabolic Optimization
Continuous monitoring is essential to titrate therapy and avoid complications. Serum sodium should be measured every 1 to 8 hours during hyperosmolar therapy to ensure the target osmotic goal is met without exceeding safety limits [43][65]D.
- Oxygen Therapy: Normobaric hyperoxia (NBO) or hyperbaric hyperoxia (HBO) may provide neuroprotection in ICH by improving metabolic function, though clinical evidence is still evolving [177].
- Temperature Control: While mild hypothermia (induced via cold saline) has been explored in large vessel occlusions, current evidence suggests it may not improve outcomes and requires further study [46].
Step 5: Refractory Management and Resolution
If first-line medical therapies fail, escalation to surgical or advanced metabolic interventions is required. This includes the placement of an EVD for CSF diversion, particularly in pediatric TBI where it is associated with better discharge outcomes [183]D. Emerging experimental therapies, such as $\beta$-Hydroxybutyrate (ketogenic diet) or aquaporin-4-modified mesenchymal stem cells, aim to restore glymphatic system function and water clearance, though these remain in the preclinical phase [74]D[86]D. Transitioning from IV to maintenance therapy occurs once imaging shows stabilization of PLE and the patient is neurologically stable [142]D.
| Drug | Dose/Route | Mechanism | Primary Indication | Evidence Level |
|---|---|---|---|---|
| Mannitol | 0.6–1.0 g/kg IV | Osmotic diuresis | Acute ICP elevation | 1b [3][176] |
| Hypertonic Saline | 3 mL/kg bolus (3%) | Osmotic gradient | Refractory edema | 1b [176] |
| Bevacizumab | Per protocol + Chemo | Anti-angiogenic | NSCLC Brain Mets | 1b [60] |
| Methylprednisolone | Pulse therapy IV | Immunomodulation | ASEM/Cytokine storm | 4 [184]C |
| Dexamethasone | Variable IV/PO | BBB stabilization | Tumor-related edema | 5 [9]D |
Surgical Management
- ▸Decompressive craniectomy for malignant MCA stroke should be performed within 48 hours to optimize survival outcomes.
- ▸Propofol-based anesthesia and hypertonic saline (3 mL/kg) are preferred intraoperatively to minimize brain swelling and improve surgical access.
- ▸Expansion craniotomy may provide superior brain volume expansion (100 cm³) compared to traditional decompressive craniectomy (72 cm³).
Surgical intervention for cerebral edema is indicated when medical management fails to control intracranial pressure (ICP) or when space-occupying lesions cause life-threatening mass effect. The primary goal is to create space for edematous brain tissue to expand, thereby preventing secondary ischemic injury and [116]D[126]D.
Step 1: Patient Selection and Timing
Early identification of patients at risk for malignant cerebral edema (MCE) is critical. In large middle cerebral artery (MCA) strokes, surgical decompression should ideally be performed within 48 hours of symptom onset to prevent early mortality [192]D. Clinical and radiological triggers for surgical consultation include a decrease in consciousness, anisocoria, and a midline shift ≥ 5 mm or pineal gland shift > 4 mm [200]D[208]D. In pediatric traumatic brain injury (pTBI), emergency surgery is frequently required for brain edema (30% of cases) and associated hematomas [189]. For patients with unruptured giant MCA aneurysms presenting with intracranial hypertension and midline shift, microsurgical vascular reconstruction or trapping may be necessary to alleviate mass effect [205]D.
Step 2: Intraoperative Optimization and Brain Relaxation
During craniotomy, achieving adequate brain relaxation is essential to prevent intraoperative "bulging brain" syndrome.
- Anesthetic Choice: Propofol-based anesthesia is preferred over volatile-based anesthesia. A meta-analysis of 17 RCTs demonstrated that propofol significantly reduces the risk of brain swelling (Risk Ratio: 0.85) [187].
- Osmotic Therapy: Administer Hypertonic Saline (HS) 3 mL/kg IV bolus or 20% Mannitol 0.6 g/kg IV after head positioning [176]. HS is often preferred for supratentorial mass surgeries as it provides superior brain relaxation compared to mannitol (Level 1b) [176]. Continuous HS infusion at 20 mL/h is also an effective alternative for maintaining relaxation [176].
Step 3: Decompressive Techniques
The choice of technique depends on the underlying pathology and the degree of swelling.
- Decompressive Craniectomy (DC): Involves removing a large bone flap (typically ≥ 12-15 cm) and performing a duraplasty. This is the standard for malignant MCA syndrome and TBI [116]D[192]D.
- Expansion Craniotomy (EC): An alternative where the bone flap is replaced but not rigidly fixed, allowing for expansion. EC has been shown to provide significantly greater brain volume increase (100 ± 51 cm³) compared to DC (72 ± 51 cm³), potentially offering superior decompression (Level 5) [126]D.
- Dynamic Craniotomy: Uses reversibly expandable plates (e.g., NuCrani) that allow the bone flap to move outward in response to swelling and return to position as edema resolves [198]D.
Step 4: Minimally Invasive and Endoscopic Options
For spontaneous intracerebral hemorrhage (sICH), minimally invasive surgery (MIS) or endoscopic evacuation may be superior to conventional craniotomy. Endoscopic surgery for large hematomas (> 50 mL) has shown feasibility and may reduce the trauma associated with large-scale decompression [199]D. MIS has been associated with reduced perihematomal edema (PHE) volumes compared to medical management alone [191]D. In cases of malignant lymphoma, neuroendoscopic biopsy allows for larger tissue samples and better hemostasis than needle biopsy, though it carries risks of postoperative edema [196]D.
Step 5: Postoperative Monitoring and Complication Management
Postoperative care focuses on ICP control and wound integrity.
- ICP Monitoring: Traditional ventricular catheters are the gold standard but carry risks of infection and hemorrhage [119]D. Emerging memristor-based implantable sensors may offer safer, portable alternatives for continuous monitoring [119]D.
- CSF Drainage: In aneurysmal subarachnoid hemorrhage (aSAH), pronounced cerebrospinal fluid (CSF) drainage via an external ventricular drain (EVD) can improve cerebral perfusion pressure (CPP) and mitigate early brain injury [206]D.
- Scalp Closure: In rare cases of intraoperative malignant edema where the scalp cannot be closed, a vacuum-assisted closure (VAC) device can be used as a temporary bridge, allowing edema to subside without sacrificing brain tissue [201]C.
Treatment Failure Protocol
If ICP remains elevated despite standard surgical decompression:
- Check Positioning: Ensure the head is midline and elevated to 30 degrees. If a large craniectomy was performed, monitor for paradoxical herniation, which may require flattening the head of the bed [116]D.
- Imaging: Obtain an immediate CT scan to rule out new contralateral hematomas or "blossoming" of existing contusions [116]D.
- Escalate Osmotics: Transition to continuous hypertonic saline infusion if not already utilized [176].
- Surgical Revision: Consider expanding the craniectomy size if the initial opening was < 12 cm, as inadequate size increases the risk of axonal stretch injury at the bone edges [116]D.
| Drug | Dose | Route | Mechanism | Evidence Level |
|---|---|---|---|---|
| Hypertonic Saline (3%) | 3 mL/kg bolus or 20 mL/h infusion | IV | Osmotic gradient; reduces ICP and improves brain relaxation | 1b [176] |
| Mannitol (20%) | 0.6 g/kg | IV | Osmotic diuresis; reduces brain water content | 1b [176] |
| Boswellia Serrata | 4050–4500 mg daily | Oral | Anti-inflammatory; used for radiation-induced edema | 5 [197]D |
Supportive Care and Complication Management
- ▸Fever prevention targeting 37.0°C is essential to limit metabolic demand and secondary injury in acute brain injury.
- ▸Rapid correction of hyperglycemia and hyperosmolarity in DKA/HHS must be avoided to prevent treatment-induced cerebral edema.
- ▸Continuous EEG monitoring is critical in comatose patients (e.g., ALF, ECMO) to detect non-convulsive status epilepticus which exacerbates edema.
The management of requires a meticulous approach to systemic homeostasis to prevent secondary brain injury. Clinicians must balance the treatment of the primary insult with the prevention of physiological triggers that exacerbate intracranial pressure (ICP). This section outlines the protocol for managing systemic factors, including temperature, glycemic control, and seizure activity, which are critical in the neurocritical care setting [212]C[214]D.
Step 1: Initial Assessment and Severity Classification
Immediate assessment must determine the risk of herniation and the etiology of the edema (e.g., vasogenic, cytotoxic, or interstitial). Severity is classified based on clinical and radiographic findings:
- Mild/Moderate: Glasgow Coma Scale (GCS) 9–15, focal edema on CT/MRI without midline shift, and preserved pupillary light reflex [209][225]D. These patients may be managed in a high-dependency unit or specialized ward with frequent neuro-checks every 1–2 hours.
- Severe: GCS ≤8, evidence of midline shift >5 mm, effacement of basal cisterns, or clinical signs of herniation (e.g., pupillary dilation, Cushing’s triad) [211]C[212]C. These patients require immediate ICU admission, invasive ICP monitoring, and potentially surgical intervention [225]D.
Step 2: Temperature Regulation and Fever Prevention
Fever is a potent driver of secondary brain injury, increasing cerebral metabolic rate and exacerbating edema [102][219]C. In patients with acute vascular brain injury, the INTREPID trial demonstrated that fever prevention is achievable using automated surface temperature management devices [102].
- Protocol: Target a core temperature of 37.0°C for at least 14 days or until ICU discharge [102].
- Rationale: Hyperthermia is implicated in the development of hemiconvulsion-hemiplegia-epilepsy (HHE) syndrome and can trigger rapid neurological deterioration in rare metabolic disorders like PEBEL2 [159]C[219]C. Maintaining normothermia reduces the metabolic demand of injured neurons and limits the proinflammatory state that worsens cytotoxic edema [219]C[226]D.
Step 3: Glycemic Control and Osmotic Stability
Metabolic disturbances, particularly in diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), are major risk factors for cerebral edema [210].
- Protocol: In DKA/HHS with baseline Osm ≥300 mOsm/L, avoid rapid drops in serum glucose and tonicity [210].
- Insulin Dosing: Administer Regular Insulin 0.1 units/kg/hr IV only after confirming potassium is ≥3.3 mEq/L [210].
- Rationale: Rapid correction of hyperglycemia leads to a precipitous drop in plasma osmolarity, creating an osmotic gradient that shifts water into the intracellular space of the brain, causing fatal edema [210]. Observational data suggest that slower correction rates may be safer, though definitive thresholds for "optimal" speed remain under investigation [210].
Step 4: Seizure Management and Prophylaxis
Seizures are both a cause and a consequence of cerebral edema. Edema, particularly in meningiomas or following ischemic stroke, is a significant prognostic factor for seizure development [105][227]D.
- Protocol: For patients with clinical seizures or status epilepticus, initiate Levetiracetam 1500 mg IV bolus followed by 500–1500 mg BID [222]D. In patients with acute liver failure (ALF) or those on ECMO, utilize continuous EEG (cEEG) to detect non-convulsive seizures, which occur in approximately 10–15% of high-risk patients [127]D[224]D.
- Rationale: Synchronized neuronal firing during seizures drives cerebrospinal fluid (CSF) influx into the brain parenchyma, worsening edema [226]D. In meningiomas, the volume of perifocal edema is a direct predictor of preoperative seizures [227]D.
Step 5: Resolution Criteria and Transition
Transition from intensive supportive care to rehabilitation should occur once the following criteria are met:
- ICP remains <20 mmHg for >24–48 hours without hyperosmolar therapy [225]D.
- GCS improves to >12 or returns to baseline.
- Radiographic resolution of midline shift and reappearance of basal cisterns.
- Rehabilitation: Early mobilization and rehabilitation should be considered, but clinicians must monitor cerebral hemodynamics during position changes, as impaired autoregulation can lead to transient ICP spikes [216]D.
Treatment Failure Protocol
If first-line supportive measures fail to stabilize ICP or neurological status:
- Escalation: Increase hyperosmolar therapy (e.g., Hypertonic Saline 3% 250 mL bolus) [225]D.
- Rescue Therapy: Consider therapeutic hypothermia (target 32–34°C) or barbiturate coma (e.g., Pentobarbital 5–20 mg/kg bolus followed by 1–4 mg/kg/hr) to suppress metabolic demand [225]D.
- Surgical Consultation: Evaluate for decompressive hemicraniectomy if edema is secondary to large vessel occlusion stroke or trauma [212]C.
What NOT to Do
- Do NOT use hypotonic fluids (e.g., 0.45% NS or D5W) as they decrease serum osmolarity and worsen cerebral edema [213]D.
- Do NOT rapidly correct severe hyponatremia; limit correction to <8–10 mEq/L per 24 hours to avoid osmotic demyelination syndrome [213]D.
- Do NOT routinely use corticosteroids for cytotoxic edema in ischemic stroke or trauma, as they lack benefit and increase infection risk [212]C[214]D. They are primarily indicated for vasogenic edema associated with tumors or ARIA [110]C[222]D.
| Drug | Dose | Route | Indication | Key ADR | Evidence Level |
|---|---|---|---|---|---|
| Mannitol 20% | 0.5–1.0 g/kg | IV Bolus | Acute ICP elevation | Renal failure, hypotension | 1b [225]D |
| Hypertonic Saline (3%) | 250 mL | IV Bolus | Acute ICP elevation | Hypernatremia, fluid overload | 1b [225]D |
| Levetiracetam | 500–1500 mg BID | IV/PO | Seizure prophylaxis/treatment | Somnolence, irritability | 2a [222]D |
| Magnesium Sulfate | 4–6 g bolus, then 1–2 g/hr | IV | Eclampsia-related edema | Loss of deep tendon reflexes | 5 [155]D[217]D |
| Dexamethasone | 4 mg every 6 hours | IV/PO | Vasogenic edema (Tumors/ARIA) | Hyperglycemia, psychosis | 4 [110]C[222]D |
Prognosis and Long-term Outcomes
- ▸Midline shift (MLS) ≥5 mm is a critical threshold for malignant progression, while MLS ≥10 mm within 24 hours indicates a surgical emergency.
- ▸In intracerebral hemorrhage, the density of perihematomal edema (measured in Hounsfield units) is a quantitative predictor of 90-day functional disability.
- ▸Malignant cerebral edema occurs in approximately 22.2% of large vessel occlusion strokes and is a primary mediator of the benefits seen with reperfusion therapy.
The prognosis of is highly variable and depends primarily on the underlying etiology, the speed of intervention, and the development of secondary brain injury. In acute settings, such as (ICH) or large hemispheric infarction, cerebral edema is a primary driver of early mortality and long-term disability. For instance, acute ICH carries a 1-month mortality rate of approximately 40%, with much of this risk attributed to the mass effect and herniation caused by perihematomal edema (PHE) [4]. In patients with large vessel occlusion (LVO) stroke, malignant cerebral edema (MCE) occurs in 22.2% of cases, significantly worsening the functional outlook [52]D.
Functional Recovery and Mortality Statistics
Functional outcomes are typically measured using the modified Rankin Scale (mRS) at 90 days or 6 months. In large hemispheric infarctions, the presence of MCE is a major mediator of poor outcomes, often resulting in an mRS score of 3–6 (moderate disability to death) [73]D. While endovascular thrombectomy (EVT) has been shown to reduce the risk of MCE, the progression of edema remains a critical determinant of whether a patient will achieve functional independence [228].
In the context of (ALF), the development of cerebral edema is a dire prognostic sign. Among patients with ALF, approximately 43.2% exhibit evidence of cerebral edema on CT imaging, and 4.5% of these patients progress to tonsillar herniation [131]. The 21-day transplant-free survival is significantly lower in patients with radiologically evident edema compared to those without [131]. Conversely, in traumatic brain injury (TBI), long-term recovery is increasingly measured by "Days Alive and at Home" (DAH), which captures the nuanced transition from hospital to various care settings over a 3-year trajectory [72]D.
Validated Prognostic Factors and Scoring Systems
Predicting the severity of cerebral edema allows for early escalation of care, such as decompressive craniectomy or intensive osmotic therapy. Several radiological and clinical markers have been validated:
- Midline Shift (MLS): An MLS ≥5 mm within 72 hours of stroke onset is a hallmark of MCE [73]D. Early severe midline shift (ES-MLS), defined as ≥10 mm within 24 hours of thrombectomy, is a life-threatening emergency associated with extremely poor functional recovery [80]D.
- Perihematomal Edema Density: In ICH, the mean Hounsfield unit (mHU) of the PHE on CT is a novel quantitative marker. Lower mHU values (indicating greater hypodensity and water content) are independently associated with unfavorable 90-day outcomes [129].
- Anatomic Involvement: Infarction involving the insula carries an odds ratio of 2.93 for developing MCE in anterior circulation strokes [52]D.
- Perilesional Edema (PLE): In patients with brain metastases treated with stereotactic radiosurgery, the presence of PLE is a significant predictor of local treatment failure (Hazard Ratio 1.83) [178].
Prognostic Assessment Protocol
Clinicians should follow a systematic approach to risk-stratify patients with evolving cerebral edema:
- Step 1: Baseline Risk Stratification: Calculate the ASPECTS score (Alberta Stroke Program Early CT Score) and NIHSS. An ASPECTS of 1–5 or an ischemic core volume >80–100 mL indicates a high risk for MCE [229][52]D.
- Step 2: Serial Imaging Monitoring: Perform follow-up CT or MRI within 24–72 hours to monitor for MLS progression and changes in edema density (mHU) [129][80]D.
- Step 3: Physiological Correlation: Monitor for "non-responders" to hyperosmolar therapy. A failure to increase serum sodium by ≥5 mEq/L after a hypertonic saline bolus (e.g., 3% NaCl 250 mL) is associated with worse intracranial pressure control [43].
- Step 4: Long-term Sequelae Screening: Evaluate for secondary complications such as post-stroke seizures, which are more frequent in patients with significant peritumoral or perilesional edema [105].
Long-term Sequelae and Recurrence
Survivors of severe cerebral edema often face a constellation of long-term challenges. In patients with meningioma, the extent of preoperative edema is a strong prognostic factor for the development of postoperative seizures [105]. Chronic edema-related changes in the basal ganglia, particularly in rare cases like dural arteriovenous fistulas (DAVF), can manifest as secondary Parkinsonism or progressive dementia [128].
Psychological impact and resource utilization are also significant. Patients with ICH who require prolonged management of cerebral edema often necessitate early gastrostomy for nutritional support, which is associated with higher healthcare resource utilization but may improve discharge disposition in select cohorts [56]D. While recurrence of the edema itself depends on the primary pathology (e.g., tumor recurrence or re-bleeding), the initial volume of edema remains one of the most reliable predictors of the permanent "disability ceiling" for the patient [228][178].
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| Midline Shift (MLS) | < 5 mm [73]D | ≥ 5 mm (MCE) or ≥ 10 mm (ES-MLS) [73]D[80]D |
| Infarct Location | Non-insular cortex | Insular cortex involvement (OR 2.93) [52]D |
| PHE Density (CT) | Higher Hounsfield Units (mHU) | Lower mHU (greater hypodensity) [129] |
| ASPECTS Score | > 7 | 1–5 (High risk for MCE) [229][52]D |
| Osmotic Response | Serum Na+ increase ≥5 mEq/L | Serum Na+ increase <5 mEq/L [43] |
| Tumor Edema | Absent/Minimal PLE | Present/Extensive PLE (HR 1.83 for failure) [178] |
Special Populations
- ▸Pediatric DKA-related cerebral edema is strongly associated with bicarbonate use and rapid insulin initiation within the first hour of treatment.
- ▸Eclampsia-related edema involves blood-brain barrier disruption potentially mediated by placental extracellular vesicles and oxidative stress.
- ▸High-altitude cerebral edema (HACE) is a medical emergency requiring immediate descent and high-dose dexamethasone (8 mg initial dose).
Cerebral edema (CE) manifests with distinct pathophysiological drivers and clinical risks across specific patient groups. Management must be tailored to account for the unique vulnerabilities of pediatric patients in metabolic crisis, the complex hemodynamics of pregnancy, and the environmental stressors of high-altitude exposure.
Pediatrics and Diabetic Ketoacidosis (DKA)
In the pediatric population, cerebral edema is the leading cause of morbidity and mortality associated with (DKA) [41], [48]. While the exact mechanism remains debated, it is often a complication of treatment rather than the metabolic state alone. Standardized clinical practice guidelines (CPGs) are essential, as they emphasize a more cautious approach to fluid and insulin administration to mitigate CE risk [41].
Risk Factors and Pathophysiology
Pediatric CE risk is significantly increased by specific therapeutic interventions. Early insulin administration (within the first hour of fluid resuscitation) and the use of bicarbonate therapy for acidosis correction are major independent risk factors [41], [252]D. Bicarbonate is particularly controversial; despite its use in severe acidosis, evidence suggests it may worsen neurological outcomes [252]D. Additionally, children with DKA often exhibit significant leukocytosis, with a high neutrophil-to-lymphocyte ratio (NLR) correlating with disease severity, though not exclusively with CE [245]. Critically ill children with DKA also face a 0.3% risk of venous thromboembolism (VTE), which can complicate the neurological clinical picture [254]D.
Management Protocol for Pediatric DKA-CE
If neurological deterioration occurs (e.g., declining GCS, bradycardia, hypertension), the following protocol should be initiated immediately:
- Step 1: Reduce the rate of IV fluid administration and elevate the head of the bed to 30 degrees.
- Step 2: Administer osmotic therapy: Mannitol 0.5–1.0 g/kg IV over 10–15 minutes or Hypertonic Saline (3%) 2.5–5 mL/kg IV over 10–15 minutes [248]D.
- Step 3: Adjust insulin delivery. For mild-to-moderate DKA, subcutaneous rapid-acting insulin analogues (RAIAs) may be considered as an alternative to IV regular insulin to provide a more gradual metabolic correction [234].
Pregnancy and Hypertensive Disorders
Cerebral edema in pregnancy is most commonly associated with and , contributing to 60–70% of maternal deaths related to these conditions [83]D. The pathophysiology involves a profound disruption of the (BBB), potentially mediated by placental extracellular vesicles that induce neuroinflammation and oxidative stress [83]D, [241]D.
Diagnostic and Clinical Considerations
Diagnosis is often complicated by the need to balance maternal stabilization with fetal safety. Ultrasonographic measurement of the optic nerve sheath diameter (ONSD) has emerged as a non-invasive tool to predict increased intracranial pressure in women with hypertensive disorders of pregnancy [237]. MRI studies in eclamptic patients frequently reveal a combination of cerebral edema, vasospasm, and even small infarcts, highlighting the multisystemic nature of the vascular insult [256]D. In rare cases, fetal macrocephaly (head circumference >98th percentile) may be detected in utero, which can occasionally be secondary to fetal cerebral edema or hydrocephalus [244]D.
High-Altitude Cerebral Edema (HACE)
High-altitude cerebral edema (HACE) is a life-threatening form of acute altitude illness occurring typically at altitudes >2500 m [104], [235]. It is characterized by the progression of (AMS) to include neurological deficits such as ataxia and altered consciousness [236], [242]D.
Pathophysiology and Presentation
HACE is driven by hypobaric hypoxia, which triggers a cascade of oxygen metabolism abnormalities, including oxidative stress, mitochondrial dysfunction, and the activation of hypoxia-inducible factor-1α (HIF-1α) [125]D, [250]D. These factors lead to increased BBB permeability and vasogenic edema [242]D. Clinical diagnosis relies on the Lake Louise Symptom Score, which evaluates headache, nausea, dizziness, and fatigue [104]. Interestingly, high-altitude retinopathy (HAR), involving retinal edema and hemorrhages, often correlates with the presence of HACE [243]D.
HACE Management Protocol
- Step 1: Immediate Descent. This is the most effective treatment. A descent of at least 500–1000 m is mandatory [236].
- Step 2: Supplemental Oxygen. Maintain SpO2 >90% if oxygen is available.
- Step 3: Pharmacotherapy. Administer Dexamethasone 8 mg IV/IM/PO initially, followed by 4 mg every 6 hours [236].
- Step 4: Hyperbaric Therapy. If descent is impossible, use a portable hyperbaric chamber (e.g., Gamow bag) [236].
Elderly and High-Altitude Residents
Elderly travelers are at risk for HACE, often complicated by pre-existing conditions such as coronary artery disease, which can exacerbate the effects of hypoxia [247]D. Furthermore, populations living permanently at high altitudes (>2500 m) may develop chronic mountain sickness (CMS), a condition distinct from HACE but involving long-term hematological and vascular adaptations to hypoxia [239], [242]D. Research into novel preventatives for HACE is ongoing, including the use of Prochlorperazine (as a respiratory stimulant) [238], Ligustrazine hydrochloride (to prevent ferroptosis) [255]D, and Hydroxychloroquine (to inhibit autophagic degradation of tight junction proteins like Claudin-5) [88]D.
| Risk Factor | Clinical Impact | Evidence Level |
|---|---|---|
| Bicarbonate Therapy | Associated with increased risk of neurological deterioration | 1c [41], [252]D |
| Early Insulin | Administration within <1 hour of fluid start increases CE risk | 1c [41] |
| Severe Acidosis | Lower initial pH and bicarbonate levels correlate with CE | 2b [48] |
| Fluid Strategy | Controversy exists between restrictive vs. permissive fluid approaches | 5 [248]D |
| Drug | Indication | Dosage |
|---|---|---|
| Dexamethasone | HACE Treatment | 8 mg initial (IV/IM/PO), then 4 mg q6h [236] |
| Acetazolamide | AMS/HACE Prevention | 125–250 mg BID [236] |
| Prochlorperazine | AMS Prevention (Experimental) | 10 mg TID [238] |
| Mannitol | Pediatric DKA-CE | 0.5–1.0 g/kg IV over 15 min [248]D |
Landmark Trials and Key Evidence
- ▸SUR1 inhibition via glibenclamide remains a primary molecular target for reducing ionic edema in large hemispheric infarctions, though phase 3 results for functional recovery were mixed [229].
- ▸Modified titration strategies for amyloid-targeting monoclonal antibodies can reduce the incidence of ARIA-E by nearly 40% [101].
- ▸Intensive blood pressure lowering to 130-140 mm Hg does not significantly reduce cerebral swelling in thrombolyzed stroke patients compared to standard targets [1].
The evidence base for managing cerebral edema has evolved from generic osmotic reduction to targeted molecular interventions and physiological optimization. Recent landmark trials have focused on inhibiting specific ion channels, modulating inflammatory cascades, and refining hemodynamic targets to mitigate both and .
CHARM: SUR1 Inhibition in Large Hemispheric Infarction
The CHARM trial (Phase 3) investigated the efficacy of intravenous glibenclamide, a potent inhibitor of the sulfonylurea receptor 1 (SUR1)-transient receptor potential melastatin 4 (TRPM4) channel [229]. This channel is upregulated following ischemic injury and is a primary driver of ionic edema.
- Design: Double-blind, placebo-controlled RCT (N=600).
- Population: Patients aged 18–85 with large hemispheric infarction (LHI) defined by ASPECTS 1–5 or core volume 80–300 mL.
- Intervention: IV glibenclamide (BIIB093) vs. placebo.
- Key Result: While the primary endpoint of 90-day functional improvement (mRS) was not met in the overall population, glibenclamide showed potential in reducing edema-related mortality in patients under 70 years [229].
- Clinical Impact: It remains the most robust investigation into molecular-targeted therapy for malignant edema, highlighting the role of SUR1 in pediatric TBI as well, where CSF SUR1 levels correlate with intracranial pressure [278].
TRAILBLAZER-ALZ 6: Mitigating ARIA-E
Amyloid-related imaging abnormalities with edema (ARIA-E) represent a unique form of iatrogenic vasogenic edema associated with monoclonal antibodies against amyloid-beta. The TRAILBLAZER-ALZ 6 trial addressed the high incidence of ARIA-E seen in earlier studies [101].
- Design: Randomized dosing regimen study (N=612).
- Intervention: Modified titration of donanemab vs. standard dosing.
- Key Result: Modified titration significantly reduced ARIA-E frequency from 24.2% to 15.6% (p=0.015) and lowered the incidence of symptomatic ARIA-E [101].
- Clinical Impact: Established that gradual titration can maintain pharmacodynamic efficacy (amyloid reduction) while significantly improving the safety profile regarding cerebral edema [273][276].
ENCHANTED: Blood Pressure Targets
The ENCHANTED trial secondary analysis explored whether intensive blood pressure (BP) control could limit the physical expansion of brain swelling in thrombolyzed acute ischemic stroke [1].
- Design: Partial factorial RCT.
- Intervention: Intensive BP lowering (target systolic 130–140 mm Hg) vs. standard care (140–180 mm Hg).
- Key Result: Intensive BP lowering did not significantly reduce the severity of cerebral swelling or midline shift compared to standard care [1].
- Clinical Impact: Suggests that while BP control is vital for preventing hemorrhage, extreme intensive lowering may not be a primary tool for edema volume reduction.
i-DEF and FAST: Insights into Perihematomal Edema (PHE)
Post hoc analyses of the i-DEF (Deferoxamine) and FAST (Factor VIIa) trials have refined our understanding of edema progression in (ICH).
- Hemoglobin and Iron: Analysis of i-DEF showed that lower baseline hemoglobin is associated with greater edema extension distance (EED), possibly due to inflammatory responses to anemia [257]. Deferoxamine was studied to chelate iron, a known driver of oxidative edema [129].
- Imaging Markers: The mean Hounsfield unit (mHU) of PHE was identified as a novel marker; lower mHU (greater hypodensity) at 72–96 hours is independently associated with poor 90-day outcomes [129].
- Sex Differences: Analysis of the FAST trial revealed that while men and women have similar baseline PHE volumes, trajectories may differ, though larger PHE volume consistently predicts worse outcomes regardless of sex [262].
SMART: Fluid Selection in TBI
The SMART trial subgroup analysis compared balanced crystalloids (e.g., Plasma-Lyte) to saline in critically ill adults with traumatic brain injury (TBI) [270].
- Rationale: There is a long-standing concern that the lower tonicity of balanced crystalloids (approx. 270–280 mOsm/L) compared to 0.9% saline (308 mOsm/L) might exacerbate cerebral edema.
- Key Result: In TBI patients, there was no significant difference in 30-day mortality or neurological discharge disposition between the two groups [270].
- Clinical Impact: Provides reassurance that balanced crystalloids may be used, though saline remains a standard for maintaining higher serum sodium levels in patients at high risk for herniation.
Emerging Neuroprotective Agents
Several phase I/II trials have recently explored novel pathways for edema reduction:
- ApTOLL (APRIL Trial): An aptamer targeting Toll-like receptor 4 (TLR4). In a secondary analysis, ApTOLL 0.2 mg/kg combined with endovascular therapy reduced final infarct volume and edema growth [258].
- YC-6: A synthetic neurosteroid (5α-androst-3β,5,6β-triol) tested in LHI. It demonstrated safety and a preliminary signal for reducing the distribution of poor mRS scores [33].
- Angong Niuhuang Pills (ANGONG Trial): A traditional Chinese medicine pilot study (3 g/day for 5 days) suggested potential reductions in edema volume in moderate-to-severe stroke [259].
Protocol: Management of ARIA-E (Based on TRAILBLAZER-ALZ 6)
Step 1 → Baseline Screening: Identify APOE ε4 carrier status and baseline microhemorrhages via MRI. Step 2 → Modified Titration: Initiate donanemab with a lower starting dose, escalating over 12–24 weeks to reach the target dose [101]. Step 3 → Surveillance Imaging: Perform MRI at weeks 4, 12, and 24 to detect asymptomatic ARIA-E. Step 4 → Intervention: If ARIA-E is detected, suspend dosing until radiographic resolution; consider corticosteroids for symptomatic cases [101].
| Trial | Year | N | Intervention | Key Finding |
|---|---|---|---|---|
| CHARM [229] | 2024 | 600 | IV Glibenclamide | Reduced edema-related death in patients <70 years with LHI. |
| TRAILBLAZER-ALZ 6 [101] | 2025 | 612 | Modified Donanemab Titration | Reduced ARIA-E frequency from 24.2% to 15.6%. |
| ENCHANTED (Sub-analysis) [1] | 2025 | 2200+ | BP 130-140 vs 140-180 | Intensive BP lowering did not reduce brain swelling. |
| SMART (TBI Subgroup) [270] | 2022 | 482 | Balanced Crystalloids vs Saline | No difference in 30-day mortality in TBI patients. |
| APRIL (ApTOLL) [258] | 2025 | 151 | ApTOLL 0.2 mg/kg | Reduced final infarct volume and edema growth. |
| INTREPID [102] | 2024 | 686 | Fever Prevention (37.0°C) | Fever prevention is achievable but did not improve 90-day mRS. |
Guidelines and Resources
- ▸Hypertonic saline is generally preferred over mannitol for the initial management of cerebral edema in traumatic brain injury, while both are acceptable in stroke and intracerebral hemorrhage.
- ▸Corticosteroids are strictly contraindicated in traumatic brain injury and ischemic stroke but remain the first-line treatment for vasogenic edema in brain tumors and high-altitude cerebral edema.
- ▸Surgical decompression for malignant MCA syndrome should be performed within 48 hours in patients aged 60 or younger to improve survival and functional outcomes.
The management of and associated is governed by several international and regional guidelines, which emphasize the importance of etiology-specific interventions and standardized monitoring protocols. While core principles such as hyperosmolar therapy and surgical decompression are widely accepted, significant practice variation exists regarding the choice of agents and the timing of interventions [225]D[296]D.
Neurocritical Care Society (NCS) 2020 Guidelines
The 2020 NCS guidelines provide a comprehensive framework for the acute treatment of cerebral edema across various neurological injuries [279]. These guidelines emphasize that clinicians must balance the efficacy of therapies with their safety profiles, particularly regarding electrolyte management and renal function.
- Hyperosmolar Therapy: For patients with (TBI), the NCS suggests using hypertonic saline (HTS) over mannitol for the initial management of elevated (ICP) or cerebral edema [279]. In contrast, for patients with (ICH) or acute ischemic stroke (AIS), either mannitol or HTS is considered acceptable [279].
- Corticosteroids: The guidelines recommend against the use of corticosteroids for cerebral edema in TBI and AIS due to lack of benefit and potential harm [279]. However, they remain the standard of care for vasogenic edema associated with brain tumors [279][285].
- Non-Pharmacologic Measures: The NCS supports the use of brief periods of hyperventilation for acute ICP crises but cautions against prolonged use [279].
Brain Trauma Foundation (BTF) 2020 Guidelines
The BTF guidelines are the primary standard for managing severe TBI [293]D. These guidelines focus on maintaining physiological thresholds to prevent secondary brain injury.
- ICP Threshold: Treatment should be initiated when ICP exceeds 22 mmHg, as values above this level are strongly associated with increased mortality [293]D.
- Cerebral Perfusion Pressure (CPP): The recommended target for CPP is between 60 and 70 mmHg [293]D. Maintaining CPP below 60 mmHg increases the risk of ischemia, while targets above 70 mmHg may lead to adult respiratory distress syndrome (ARDS) due to aggressive fluid and pressor use.
- Surgical Decompression: Large-frontoparietal (at least 12 x 15 cm or 15 cm in diameter) is recommended over smaller bone flaps to effectively reduce ICP and improve functional outcomes [293]D[298]D.
AHA/ASA Guidelines for Stroke and Hemorrhage
The American Heart Association and American Stroke Association (AHA/ASA) provide specific recommendations for edema management in vascular emergencies [283][211]C.
- Malignant MCA Syndrome: For patients ≤60 years of age with massive middle cerebral artery (MCA) territory infarction who deteriorate neurologically within 48 hours, decompressive hemicraniectomy is strongly recommended [283].
- Cerebellar Infarction: Neurosurgical consultation is mandatory for large cerebellar infarcts with swelling; suboccipital craniectomy should be performed if there is evidence of brainstem compression or obstructive hydrocephalus [283].
- Subarachnoid Hemorrhage (SAH): Recent 2023/2024 updates emphasize avoiding a lower limit of perfusion and protocolizing the detection of delayed cerebral ischemia [211]C[294]D.
Wilderness Medical Society (WMS) and Environmental Guidelines
Specific guidelines exist for cerebral edema occurring in austere environments, such as high-altitude cerebral edema (HACE) and exercise-associated hyponatremia (EAH).
- HACE Management: The 2019 WMS update identifies immediate descent as the most critical intervention [287]. Pharmacologic management includes dexamethasone 8 mg (IV, IM, or PO) followed by 4 mg every 6 hours until symptoms resolve [287][290].
- Hyponatremia: The European Society of Intensive Care Medicine (ESICM) and WMS define hyponatremia as serum sodium <135 mmol/L [281][289]. For symptomatic hyponatremic encephalopathy, the recommended treatment is a bolus of 150 mL of 3% hypertonic saline, which can be repeated to achieve a rapid rise of 5 mmol/L in serum sodium [281][282].
Specialty and Poisoning Guidelines
- Acute Liver Failure (ALF): The U.S. Acute Liver Failure Study Group recommends ICP monitoring in patients with advanced (Grade 3 or 4) who are candidates for liver transplantation [284].
- Valproic Acid Poisoning: The EXTRIP workgroup recommends extracorporeal treatment (ECTR), such as hemodialysis, if serum valproic acid levels exceed 850 mg/L or if cerebral edema is present [280].
Clinical Management Protocol for Acute Cerebral Edema
Based on a synthesis of NCS and BTF recommendations [279][293]D:
- Step 1: Tier 1 Interventions
- Elevate head of bed to 30 degrees to optimize venous drainage.
- Ensure adequate sedation and analgesia to minimize sympathetic surges.
- Maintain normothermia and normoglycemia.
- Step 2: Tier 2 Interventions (Osmotherapy)
- Administer mannitol 0.25 to 1 g/kg IV or hypertonic saline (3% or 23.4%) boluses [279].
- Monitor serum osmolality (target <320 mOsm/kg for mannitol) and serum sodium (target <155-160 mEq/L for HTS).
- Step 3: Tier 3 Interventions (Refractory Edema)
- Consider surgical decompression (craniectomy) [298]D.
- Initiate metabolic suppression (e.g., pentobarbital coma) if surgical options are exhausted or inappropriate.
- Consider mild hypothermia (32-35°C) as a rescue therapy, though evidence for routine use is limited [279].
| Guideline | Organization | Year | Key Recommendations |
|---|---|---|---|
| Acute Cerebral Edema | Neurocritical Care Society (NCS) | 2020 | Favors HTS for TBI; either HTS or Mannitol for ICH/AIS; against steroids for TBI/AIS [279]. |
| Severe TBI | Brain Trauma Foundation (BTF) | 2020 | ICP threshold 22 mmHg; CPP target 60-70 mmHg; against steroids; favors large DC [293]D. |
| Ischemic Stroke Swelling | AHA/ASA | 2014 | Decompressive craniectomy for malignant MCA in age ≤60; mandatory surgery for cerebellar swelling [283]. |
| Hyponatremia | ESICM / ESE / ERA-EDTA | 2014 | 3% HTS bolus for symptomatic edema; limit correction to 10 mmol/L/24h [281]. |
| Altitude Illness (HACE) | Wilderness Medical Society (WMS) | 2019 | Immediate descent; Dexamethasone 8 mg then 4 mg q6h [287]. |
| Brain Metastases | EFNS | 2006 | Dexamethasone is the corticosteroid of choice for associated edema [285]. |
| VPA Poisoning | EXTRIP Workgroup | 2015 | Hemodialysis (ECTR) if VPA > 850 mg/L or cerebral edema present [280]. |
References
- [1]
Zhang G, Chen C, Ren X et al.. “Effects of Intensive Blood Pressure Lowering on Brain Swelling in Thrombolyzed Acute Ischemic Stroke: The ENCHANTED Results.” Stroke (2025). PMID: 40177745 ↗
L1bRCTCited in: Definition, Synonyms, and Classification, History and Physical Examination, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [2]
Peng X, Zhu R, Zhang K et al.. “Global collaboration and innovation in malignant cerebral edema research: a bibliometric perspective.” Frontiers in neurology (2025). PMID: 40771971 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Krishnan K, Grace E, Woodhouse L et al.. “Baseline characteristics of patients recruited to the mannitol for cerebral oedema after acute intracerebral haemorrhage (MACE-ICH) trial.” Clinical neurology and neurosurgery (2026). PMID: 41690237 ↗
L1bRCTCited in: Definition, Synonyms, and Classification, Medical Management, Prognosis and Long-term Outcomes - [4]
Krishnan K, Grace E, Woodhouse L et al.. “Mannitol for cerebral oedema after acute intracerebral haemorrhage (MACE-ICH): protocol for a prospective, randomised, open-label, blinded-endpoint phase IIb trial.” BMJ open (2025). PMID: 40721251 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification, Medical Management, Prognosis and Long-term Outcomes - [5]
Ibarra F, Hsu J, Jassal A et al.. “Comparison of 8.4% Sodium Bicarbonate vs. 3% Sodium Chloride in Severe Hyponatremia: A Retrospective Cohort Study.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 41937305 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [6]
Lu L, Ou H, Wang X et al.. “The impact of sulfonylureas on survival in patients with severe ischemic stroke and type 2 diabetes: A retrospective study based on the MIMIC-IV database.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2025). PMID: 40618539 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors - [7]
Qin W, Zhao Y, Du J et al.. “Insights into the potential pathogenesis and therapeutic implications of ferroptosis in brain microvascular endothelial cells during stroke.” Frontiers in immunology (2026). PMID: 41836429 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors, Pathophysiology - [8]
Sterns RH, Rondon-Berrios H. “Revisiting New Data on the Mortality Benefit of Rapid Correction of Hyponatremia: Déjà Vu All Over Again.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2026). PMID: 41093163 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors - [9]
Prasath S, Harsha SP, Swamy AM et al.. “Revisiting the use of steroids in oncology.” Medical oncology (Northwood, London, England) (2025). PMID: 41452544 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Medical Management - [10]
García Ríos CA, Leon-Rojas JE. “Aquaporin-4 in Stroke and Brain Edema-Friend or Foe?” International journal of molecular sciences (2025). PMID: 40943104 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Pathophysiology - [11]
Yang Z, Li P, Wei J. “Perceiving traumatic brain injury from glymphatic system.” Molecular psychiatry (2025). PMID: 40745390 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Pathophysiology - [12]
Datta D, John CC. “Pathogenesis of brain injury in cerebral malaria: emerging mechanisms and implications for intervention.” Current opinion in infectious diseases (2025). PMID: 40742185 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Pathophysiology - [13]
Coupland KG, Amell MF, Spratt NJ. “Brain fluid physiology in ischaemic stroke; more than just oedema.” Fluids and barriers of the CNS (2025). PMID: 40533800 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [14]
Sen BK, Pan K, Chakravarty A. “Hepatic Encephalopathy: Current Thoughts on Pathophysiology and Management.” Current neurology and neuroscience reports (2025). PMID: 40153081 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [15]
Kasuda K, Saito R, Nishiyama T et al.. “Liver Transplantation for Acute Liver Failure After Intentional Iron Overdose: A Case Report and Literature Review.” Pediatric transplantation (2025). PMID: 41039699 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [16]
Barragán C, González-Gómez S, Barrera A et al.. “Reversible intramyelinic cytotoxic edema in a patient with traumatic brain injury.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40610848 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification, Diagnosis and Workup - [17]
Micovic M, Zivkovic B, Vukasinovic I et al.. “Trauma-Induced Cerebellar Edema: A Rare Presentation of Infratentorial Developmental Venous Anomaly in a Pediatric Patient.” Cerebellum (London, England) (2025). PMID: 40387982 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification, Diagnosis and Workup - [18]
Zhang Y, Chen R, Kong X et al.. “Rapid-onset hypernatremia induced by central diabetes insipidus leading to osmotic demyelination syndrome: a case report.” Frontiers in medicine (2025). PMID: 40370728 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification - [19]
Kurdi M, Kabli A, Alkhotani A et al.. “Impact of corticosteroid administration on glioblastoma progression before and after adjuvant treatments: recent updates on contradictory findings and mechanistic interactions.” Frontiers in oncology (2026). PMID: 41847699 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [20]
Silva BKO, de Carvalho MCS, Delgado AF et al.. “Neurologic monitoring in children and adolescents with hepatic failure: new mechanisms and non-invasive approach.” Clinics (Sao Paulo, Brazil) (2025). PMID: 41297473 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Diagnosis and Workup - [21]
Zeng L, Yin Z, Li W et al.. “Glymphatic system function in patients with ischemic stroke evaluated by the DTI-ALPS method: a comprehensive review.” Frontiers in neurology (2025). PMID: 41064036 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [22]
Abdelhakim N, Galecio-Castillo M, Kalakoti P et al.. “Cytotoxic Edema and Intra-parenchymal Hemorrhage: A Mediated Pathway to Mortality and Functional Outcome in Cerebral Venous Sinus Thrombosis- A sub-analysis of the CLOT-VENUS Registry.” Translational stroke research (2026). PMID: 41975110 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [23]
Tan Y, Ye H, Ge Q et al.. “Multimodal MR Imaging Reveals the Mechanisms of Post-Cardiac-Arrest Brain edema: Ferroptosis-Mediated BBB Disruption and AQP4 Dysfunction.” Journal of magnetic resonance imaging : JMRI (2026). PMID: 41933462 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [24]
Shen W, Jiang C, Liu X et al.. “Astragaloside IV alleviates post-traumatic cytotoxic edema via inhibition of AQP4 expression and subcellular localization.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 41916121 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [25]
Nakagawa M, Tomura S, Toyooka T et al.. “Preconditioning Effect of Hydrogen Gas on Traumatic Brain Injury.” Journal of neurotrauma (2026). PMID: 41877520 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [26]
Dayyani M, Filippov A, Zhang I et al.. “RAGE Inhibition Reduces Surgery-Induced Cerebral Edema After Glioma Resection.” Neurosurgery (2026). PMID: 41854274 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [27]
Lin XY, Usman M, Ai L et al.. “Experimental Study on Changes in the Structure of the Blood-Brain Barrier after Treatment with Bevacizumab for Traumatic Cerebral Edema.” Neurocritical care (2026). PMID: 41673382 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [28]
Poulain A, Riseth J, Emblem KE et al.. “Modeling glioma-induced impairments on the glymphatic system.” Fluids and barriers of the CNS (2026). PMID: 41612346 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors, Pathophysiology - [29]
Palazzo C, Pati R, Gatta RP et al.. “Acute Dehydration Drives Organ-Specific Modulation of Phosphorylated AQP4ex in Brain and Kidney.” International journal of molecular sciences (2026). PMID: 41596269 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Pathophysiology - [30]
Cohen C, Debacker C, Le Berre A et al.. “Revisiting the Optimal Apparent Diffusion Coefficient Threshold for Ischemic Core Delineation.” Neurology (2026). PMID: 41453127 ↗
L5OTHERCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors, Diagnosis and Workup - [31]
Hegazi A, Mohamed RG, Kashbour M et al.. “Efficacy and Safety of Glibenclamide on Functional Outcomes and Cerebral Edema following Ischemic and Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Medical principles and practice : international journal of the Kuwait University, Health Science Centre (2026). PMID: 40720947 ↗
L1aSR_MA_RCTCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [32]
Sweety S, Panda S, Das RR. “Balanced electrolyte solution vs isotonic saline in the resuscitation of children with diabetic ketoacidosis: A randomized controlled trial.” World journal of clinical pediatrics (2026). PMID: 41884024 ↗
L1bRCTCited in: Epidemiology and Risk Factors - [33]
Hou H, Feng B, Zang D et al.. “Safety and Feasibility of YC-6 in Patients With Large Hemispheric Infarction: A Randomized Clinical Trial.” Journal of the American Heart Association (2025). PMID: 41147407 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [34]
Falcão L, Gomes PAL, Silva RAS et al.. “Assessing Glibenclamide's efficacy on functional recovery in aneurysmal subarachnoid hemorrhage: A meta-analysis of randomized controlled trials.” Clinical neurology and neurosurgery (2025). PMID: 40107191 ↗
L1aSR_MA_RCTCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [35]
Mohammed HE, Haseeb ME, Bady Z et al.. “The Efficacy and Safety of Glibenclamide in Improving Cerebral Edema and Neurological Outcomes in Stroke: a GRADE-Evaluated Systematic Review and Meta-analysis with Subgroup Analysis.” Neurocritical care (2025). PMID: 40629214 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [36]
Chen Y, Mofatteh M, Dai Y et al.. “Decompressive craniectomy after endovascular thrombectomy in acute ischemic stroke: a systematic review.” Acta neurochirurgica (2025). PMID: 40622611 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Surgical Management - [37]
Song W, Liu Y, Kang C et al.. “Efficacy and safety of Shuxuening injection in intracerebral hemorrhage: a systematic review and meta-analysis.” Frontiers in pharmacology (2025). PMID: 40458793 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [38]
Shafieioun A, Ghaffari H, Baradaran M et al.. “Predictive power of artificial intelligence for malignant cerebral edema in stroke patients: a CT-based systematic review and meta-analysis of prevalence and diagnostic performance.” Neurosurgical review (2025). PMID: 40128510 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [39]
Dupont J, Dinkova M, Tabillon C et al.. “Infection following a stereotactic brain biopsy: Myth or reality? Retrospective study between 2009 and 2023.” Anaesthesia, critical care & pain medicine (2026). PMID: 41022203 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Medical Management, Surgical Management - [40]
Qin J, Li C, Fu J et al.. “Construction and application of a nomogram model for predicting postoperative cerebral edema in meningiomas based on radiomics and clinical features.” Acta radiologica (Stockholm, Sweden : 1987) (2025). PMID: 40474660 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Prognosis and Long-term Outcomes - [41]
Fustiñana AL, Echeveste JR, Pedalino J et al.. “Implementation of a Clinical Practice Guideline for diabetic ketoacidosis at a tertiary pediatric hospital: a before-after study.” Andes pediatrica : revista Chilena de pediatria (2025). PMID: 41842793 ↗
L1cGUIDELINECited in: Epidemiology and Risk Factors, Special Populations - [42]
Bicknell BT, Malepati A, Taylor MA et al.. “Diagnostic and Prognostic Value of Retinal and Intracranial Hemorrhages in Abusive Head Trauma: A Retrospective Study.” Journal of pediatric ophthalmology and strabismus (2026). PMID: 41817138 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [43]
Feininger ES, May CC, Hinduja A et al.. “Risk factor analysis of hypertonic saline non-responders for the treatment of cerebral edema: a retrospective cohort study.” International journal of clinical pharmacy (2026). PMID: 41379290 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Medical Management, Prognosis and Long-term Outcomes - [44]
Raja J, Mishra R, Kamath S et al.. “Incidence, predictors, and impact of cerebral edema during the early brain injury phase of aneurysmal subarachnoid hemorrhage: A retrospective cohort study.” Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2026). PMID: 41352133 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [45]
Liu Z, Lin Y, Duan X et al.. “Predictors of Malignant Cerebral Edema Following Mechanical Thrombectomy in Acute Ischemic Stroke: A Retrospective Study and Nomogram Development.” World neurosurgery (2026). PMID: 41274648 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Prognosis and Long-term Outcomes - [46]
Li J, Zhang W, Tang SN et al.. “Endovascular Interventional Thrombolysis Combined With Mild Hypothermia Induced by Intravascular Hypothermia Saline Fails to Improve Outcomes in the Acute Large Vessel Occlusive Cerebral Infarction Patients: A Single-Center Prospective Case-Control Study.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40999632 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors, Medical Management, Prognosis and Long-term Outcomes - [47]
Lu R, Yan J, Wang S et al.. “Two cases of acute pancreatitis occurring during therapeutic hypothermia for severe brain injury: case report and literature review.” Frontiers in medicine (2026). PMID: 41919147 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors - [48]
Memarian S, Zolfaghari A, Gharib B et al.. “The incidence of cerebral edema in pediatric patients with diabetic ketoacidosis: a retrospective study.” BMC research notes (2025). PMID: 40205526 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Special Populations - [49]
Ali NM, Alhag MH, Mustafa AE et al.. “Prevalence, Clinical Profile, and Outcomes of Diabetic Ketoacidosis (DKA) in Pediatric ICU Patients in the Middle East: A Systematic Review and Meta-Analysis.” Cureus (2026). PMID: 41859577 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [50]
Zhang X, Li C, Wang Y et al.. “No-reflow phenomenon after vessel recanalization in acute ischemic stroke: mechanisms, diagnosis, and treatment directions.” Journal of neurology (2026). PMID: 41915244 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Etiology and Triggering Factors - [51]
Trivedi A, Miyazawa BY, Zhang H et al.. “A Dried Platelet-Derived Biologic for Blood-Brain Barrier Repair and Hemorrhage Control Following TBI in Mice.” Blood (2026). PMID: 41843452 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [52]
Luo B, Cui W, Zhang M et al.. “Insular infarction synergistically amplifies malignant cerebral edema risk in anterior circulation large vessel occlusion.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2026). PMID: 41763340 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [53]
Al-Salahat A, Cheung R, Dilsaver DB et al.. “Factors associated with mortality in posterior reversible encephalopathy syndrome: a nationwide analysis.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2026). PMID: 41731090 ↗
L5OTHERCited in: Epidemiology and Risk Factors, History and Physical Examination, Differential Diagnosis, Medical Management - [54]
Schmitt LG, Dohopolski M, de Vis J et al.. “Adaptive MRI-Guided Reirradiation for High-Risk Recurrent Grade 4 Gliomas: Early Clinical Outcomes and Volumetric Response.” International journal of radiation oncology, biology, physics (2026). PMID: 41663034 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [55]
Liang J, Zhong S, Lian Y et al.. “Episodic encephalopathy in NOTCH2NLC-related neuronal intranuclear inclusion disease: Clinical spectrum and a proposed classification framework.” Journal of the neurological sciences (2026). PMID: 41455460 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup - [56]
Loggini A, Del Brutto VJ, Velez FGS et al.. “Early gastrostomy is associated with more efficient healthcare resource utilization in nontraumatic intracerebral hemorrhage patients.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2026). PMID: 41448379 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Medical Management, Prognosis and Long-term Outcomes - [57]
Burst V, Rabii R, Peto-Madew J et al.. “Severe Hyponatremia in the Emergency Department Incidence of Cerebral Edema and Risk of Osmotic Demyelination Syndrome.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 41069084 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Medical Management - [58]
Takeuchi I, Muraoka S, Kinoshita F et al.. “Efficacy of combined clazosentan and cilostazol therapy for cerebral vasospasm after subarachnoid hemorrhage: a retrospective multicenter registry study.” Journal of neurosurgery (2026). PMID: 40972040 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Medical Management - [59]
Dabbagh Ohadi MA, Soleimani S, Kakoienejad MM et al.. “Clinical benefits of photodynamic therapy in glioblastoma: systematic review and meta-analysis.” Journal of neurosurgery (2026). PMID: 41569684 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors, Medical Management, Prognosis and Long-term Outcomes - [60]
Li M, Pan Y, Jiang G et al.. “Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.” ESMO open (2025). PMID: 41270700 ↗
L1bRCTCited in: Etiology and Triggering Factors, Medical Management, Landmark Trials and Key Evidence - [61]
Gigliotti MJ, Jareczek FJ. “Indications and Timing in Ischemic Infarction and Other Disorders.” Neurosurgery clinics of North America (2026). PMID: 41967892 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [62]
Yan X, Shen H, Zhao M et al.. “Time Is of the Essence: Temporal Dynamics of Epigenetic Landscapes as Therapeutic Targets in Traumatic Brain Injury.” ACS chemical neuroscience (2026). PMID: 41565603 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [63]
Arbogast A, Montoya Rush MN, Ghosh S et al.. “Cerebrovascular Unit Activation and Response Following Traumatic Brain Injury.” Shock (Augusta, Ga.) (2026). PMID: 41166163 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [64]
Shi Y, Liang T, Shi C et al.. “Molecular mechanisms of streptococcal disruption of the blood-brain barrier and their pathogenic role in bacterial meningitis.” Frontiers in immunology (2025). PMID: 41573555 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology - [65]
Henry DA. “Hyponatremia.” Annals of internal medicine (2025). PMID: 41359965 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Medical Management - [66]
Najjar M, Fleming M. “Pediatric stroke: From emergent evaluation to rehabilitation.” Current problems in pediatric and adolescent health care (2025). PMID: 41353016 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Medical Management - [67]
Pang L, Xu X, Liu Y et al.. “A case report and literature review of neuropsychiatric lupus presenting with coma as the initial symptom.” Medicine (2026). PMID: 41560092 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [68]
Chen Y, Yin X, Zhang E et al.. “Astrocyte-Derived Exosomal miR-211-5p Alleviates Blood-Brain Barrier Injury in a Rat Model of Traumatic Brain Injury.” CNS neuroscience & therapeutics (2026). PMID: 41954515 ↗
L5OTHERCited in: Etiology and Triggering Factors, Pathophysiology - [69]
Bai J, Xie N, Hou Y et al.. “SnRNA-seq reveals the ameliorative effects of optimized Xueyu Jingshen formula on high altitude cerebral edema by modulating energy metabolism, inflammation and BBB integrity.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 41720010 ↗
L5OTHERCited in: Etiology and Triggering Factors, Pathophysiology, Special Populations - [70]
Li X, Gao Y, Ye Y et al.. “Cyanidin-3-glucoside confers neuroprotection in ischemic stroke by targeting NOX4-mediated oxidative stress: A network pharmacology and experimental validation study.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2026). PMID: 41616469 ↗
L5OTHERCited in: Etiology and Triggering Factors - [71]
Zhou YF, Yang SB, Zhang F et al.. “Microvascular endothelial metabolic dysfunction drives cerebral edema through bioenergetic failure after ischemia-reperfusion.” Theranostics (2026). PMID: 41608584 ↗
L5OTHERCited in: Etiology and Triggering Factors - [72]
Malhotra AK, Nathens AB, Shakil H et al.. “Predicting Return Home After Moderate-to-Severe Traumatic Brain Injury.” Neurology (2026). PMID: 41604614 ↗
L5OTHERCited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes - [73]
Xu X, Xu X, Ma J et al.. “Clinical Benefit of Thrombectomy in Large-Core Infarction Patients Is Mediated by Malignant Cerebral Edema Reduction.” Journal of the American Heart Association (2026). PMID: 41568548 ↗
L5OTHERCited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes - [74]
Yu MJ, Xiong RQ, Wu JW et al.. “β-Hydroxybutyrate improves glymphatic system function and alleviates cerebral edema in mice after ischemic stroke.” Acta pharmacologica Sinica (2026). PMID: 41535708 ↗
L5OTHERCited in: Etiology and Triggering Factors, Pathophysiology, Medical Management - [75]
Petersen NH, Begunova L, Olexa M et al.. “Autoregulation-Guided Blood Pressure Targets After Stroke Thrombectomy: Impact on Secondary Brain Injury and Neurologic Outcomes.” Neurology (2026). PMID: 41512207 ↗
L5OTHERCited in: Etiology and Triggering Factors, History and Physical Examination, Prognosis and Long-term Outcomes - [76]
Shang H, Xu R, Niu H et al.. “20(S)-Protopanaxadiol regulating glucocorticoid receptor attenuates ischemic stroke injury by alleviating the autophagy-lysosomal pathway dysfunction and neuroinflammation.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 41499936 ↗
L5OTHERCited in: Etiology and Triggering Factors - [77]
Jin L, Yang Z, Wei B et al.. “Amelioration of Post-Stroke Edema and Microcirculatory Dysfunction via Targeted AQP4 Inhibition While Preserving the Glymphatic System.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41387988 ↗
L5OTHERCited in: Etiology and Triggering Factors, Pathophysiology - [78]
Banderwal R, Kumar A. “Neuroprotective mechanism of syringic acid targeting oxidative damage and neuroinflammation in an experimental model of traumatic brain injury.” Inflammopharmacology (2026). PMID: 41369867 ↗
L5OTHERCited in: Etiology and Triggering Factors - [79]
Zhang X, Liu B, Shao D et al.. “Anti-inflammatory and neuroprotective effect of bryodulcosigenin against cerebral ischemia/reperfusion injury via modulation of inflammatory signaling pathways.” Inflammopharmacology (2026). PMID: 41269478 ↗
L5OTHERCited in: Etiology and Triggering Factors, Pathophysiology - [80]
Han N, Zhang X, Zhang Y et al.. “Predicting early severe midline shift in acute ischemic stroke Within 24 h of endovascular thrombectomy.” Neuroradiology (2026). PMID: 41201490 ↗
L5OTHERCited in: Etiology and Triggering Factors, Diagnosis and Workup, Prognosis and Long-term Outcomes - [81]
Viveros-Bartolomé JM, Pérez-Mora S, Alquisiras-Burgos I et al.. “Extract of Bacopa procumbens Mitigates Brain Injury and Improves Functional Outcomes Following Ischemia-Reperfusion.” International journal of molecular sciences (2025). PMID: 41465215 ↗
L5OTHERCited in: Etiology and Triggering Factors - [82]
Li M, Huo X, Zhao X et al.. “Nr1d1 Regulates Microglia M1/M2 Polarization to Alleviate Neuroinflammation after Traumatic Brain Injury.” ACS chemical neuroscience (2025). PMID: 41296614 ↗
L5OTHERCited in: Etiology and Triggering Factors - [83]
Escudero C, Vatish M. “Review: The potential role of placental extracellular vesicles in blood-brain barrier disruption and neuroinflammation in preeclampsia.” Placenta (2026). PMID: 40229181 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Special Populations - [84]
Weiss A, Ding Y. “Beyond Reperfusion: Adjunctive Therapies Targeting Inflammation, Edema, and Blood-Brain Barrier Dysfunction in Ischemic Stroke.” Cerebrovascular diseases (Basel, Switzerland) (2026). PMID: 40609526 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [85]
Huang R, Gao L, Dai Y et al.. “Olink Proteomics Reveals CCL2 Aggravates Perihematomal Edema After Intracerebral Hemorrhage in High-Altitude Migrants Via CCR2/NF-κB-Mediated Blood-Brain Barrier Disruption.” CNS neuroscience & therapeutics (2026). PMID: 41944579 ↗
L5OTHERCited in: Pathophysiology - [86]
Li Y, Yang W, Tang Y et al.. “Aquaporin-4-overexpressing mesenchymal stem cells promote neurological recovery after intracerebral hemorrhage by inhibiting TLR4/NF-κB signaling.” Free radical biology & medicine (2026). PMID: 41380917 ↗
L5OTHERCited in: Pathophysiology, Medical Management - [87]
Bevers MB, An J, Yoo A et al.. “Brain Endothelial Soluble ST2 Production and Cerebral Edema in a Rat Model of Ischemic Stroke.” Annals of neurology (2026). PMID: 40833219 ↗
L5OTHERCited in: Pathophysiology - [88]
Xue Y, Wan B, Wang Z et al.. “Hydroxychloroquine Prevents High-altitude Cerebral Edema by Inhibiting Endothelial Claudin-5 Autophagic Degradation.” Current neuropharmacology (2026). PMID: 40353467 ↗
L5OTHERCited in: Pathophysiology, Special Populations - [89]
Guo P, Siddique R, Qian J et al.. “Apelin-13 Attenuates Blood-Brain Barrier Dysfunction Following Intracerebral Hemorrhage via Targeting the Keap1/Nrf2 Signaling.” CNS neuroscience & therapeutics (2025). PMID: 41459616 ↗
L5OTHERCited in: Pathophysiology - [90]
Wu Y, Lv W, Xiong S et al.. “Dalbergia odorifera T.C. Chen leaf extract promotes microglial energy expenditure to phagocytize neutrophils after cerebral ischemia-reperfusion.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2025). PMID: 41253024 ↗
L5OTHERCited in: Pathophysiology - [91]
Hou X, Mo X, Zhang X et al.. “Cuproptosis-driven astrocyte reactivity exacerbates experimental cerebral malaria pathogenesis.” Parasites & vectors (2025). PMID: 41214704 ↗
L5OTHERCited in: Pathophysiology - [92]
Wu JW, Zhou YT, Wang BX et al.. “Apigenin regulates CCR5/JAK1/STAT1/MMPs signaling to alleviate secondary brain injury after intracerebral hemorrhage and its enhanced delivery via targeted nanoparticles.” Journal of nanobiotechnology (2025). PMID: 41177867 ↗
L5OTHERCited in: Pathophysiology - [93]
Michinaga S, Takahashi K, Ogawa Y et al.. “Smoothened Agonist Treatment Mitigates Vasogenic Edema, Neuroinflammation, and Neurological Dysfunction Following Traumatic Brain Injury in Mice.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2025). PMID: 41134710 ↗
L5OTHERCited in: Pathophysiology - [94]
Yang Y, Chen L, Hou P et al.. “Effects of Irrigation With Normal Saline on Traumatic Brain Injury Combined With Seawater Immersion in Rats.” The Journal of surgical research (2025). PMID: 41073193 ↗
L5OTHERCited in: Pathophysiology, Medical Management - [95]
Zhang Y, Wang L, Li D et al.. “Bispecific self-assembled peptides as supra-growth factors for preventing endotheliopathy and improving survival of traumatic brain injury in mice.” Journal of nanobiotechnology (2025). PMID: 41068806 ↗
L5OTHERCited in: Pathophysiology - [96]
Wang J, Li L, Xu J et al.. “Neutrophil extracellular traps induce endothelial damage and exacerbate vasospasm in traumatic brain injury.” Theranostics (2025). PMID: 40963908 ↗
L5OTHERCited in: Pathophysiology - [97]
Zhang L, Shao Y, Fang Z et al.. “Salvianolic Acid B and Ginsenoside Rg1 Combination Attenuates Cerebral Edema Accompanying Glymphatic Modulation.” Neuroscience bulletin (2025). PMID: 40886214 ↗
L5OTHERCited in: Pathophysiology - [98]
Robinson BD, Yeager A, Lomas A et al.. “Quercetin Protects Blood-Brain Barrier Integrity and Maintains Microvascular Permeability Following Traumatic Brain Injury.” Neurocritical care (2025). PMID: 40739078 ↗
L5OTHERCited in: Pathophysiology - [99]
Xue YF, Wu YX, Zhang YZ et al.. “Gper1 inhibition exacerbates traumatic brain injury-induced neurological impairments in mice.” Behavioral and brain functions : BBF (2025). PMID: 40605012 ↗
L5OTHERCited in: Pathophysiology - [100]
Li Y, Zhou H, Xie J et al.. “Targeting TRPV4 to restore glymphatic system function and alleviate cerebral edema in ischemic stroke.” Brain pathology (Zurich, Switzerland) (2025). PMID: 40481713 ↗
L5OTHERCited in: Pathophysiology - [101]
Wang H, Nery ESM, Ardayfio P et al.. “The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6.” The journal of prevention of Alzheimer's disease (2025). PMID: 40619285 ↗
L1bRCTCited in: History and Physical Examination, Landmark Trials and Key Evidence - [102]
Greer DM, Helbok R, Badjatia N et al.. “Fever Prevention in Patients With Acute Vascular Brain Injury: The INTREPID Randomized Clinical Trial.” JAMA (2024). PMID: 39320879 ↗
L1bRCTCited in: History and Physical Examination, Supportive Care and Complication Management, Landmark Trials and Key Evidence - [103]
Yun J, Kim KH, Jung JW et al.. “Effects of blood pressure lowering in patients treated with intravenous thrombolysis before endovascular thrombectomy.” International journal of stroke : official journal of the International Stroke Society (2025). PMID: 39819210 ↗
L2bTRIAL_NONRANDOMCited in: History and Physical Examination, Prognosis and Long-term Outcomes - [104]
Łagowski W, Grodzka O, Domitrz I. “Atypical neurological symptoms at high altitude: a systematic literature review.” Travel medicine and infectious disease (2025). PMID: 40379194 ↗
L2aSR_OBSCited in: History and Physical Examination, Special Populations - [105]
Tanti MJ, Nevitt S, Yeo M et al.. “Oedema as a prognostic factor for seizures in meningioma - a systematic review and meta-analysis.” Neurosurgical review (2025). PMID: 39969698 ↗
L2aSR_OBSCited in: History and Physical Examination, Supportive Care and Complication Management, Prognosis and Long-term Outcomes - [106]
Song X, Wang Y, Guo W et al.. “Time-varying association between blood pressure and malignant brain edema after large hemispheric infarction: a prospective cohort study.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40155579 ↗
L2bCOHORTCited in: History and Physical Examination - [107]
Evans AS, Singh S, Joshi C et al.. “Examining Clinical Features and Severe Neurologic Disease of Parechovirus Infection in Young Infants: A Multistate Cohort Study.” Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024). PMID: 39093815 ↗
L2bCOHORTCited in: History and Physical Examination, Supportive Care and Complication Management - [108]
Rajendran G, Mahalingam S, Ramkumar A et al.. “Diagnostic Accuracy of Optic Nerve Sheath Diameter Using Ultrasonography for Raised Intracranial Pressure in Pediatric Patients - A Systematic Review and Meta-Analysis.” World neurosurgery (2024). PMID: 39142382 ↗
L2aSR_OBSCited in: History and Physical Examination - [109]
Capece G, Caumo L, Volta S et al.. “Wernicke Encephalopathy Complicating a Distinctive POLG Phenotype With MNGIE-Like Features.” European journal of neurology (2026). PMID: 41841518 ↗
L4CASE_REPORTCited in: History and Physical Examination - [110]
Gibson AW, Elser H, Rosso M et al.. “Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab.” Alzheimer's & dementia : the journal of the Alzheimer's Association (2024). PMID: 39215494 ↗
L4CASE_REPORTCited in: History and Physical Examination, Supportive Care and Complication Management - [111]
Rohm Z, Goldman MD, Riley C et al.. “A 73-Year-Old Woman With Confusion, Visual Field Disturbances, and Edematous White Matter Lesions: From the National Multiple Sclerosis Society Case Conference Proceedings.” Neurology(R) neuroimmunology & neuroinflammation (2024). PMID: 39141887 ↗
L4CASE_REPORTCited in: History and Physical Examination - [112]
Diorio C, Hernandez-Miyares L, Espinoza DA et al.. “Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescents.” Blood (2024). PMID: 38905637 ↗
L4CASE_REPORTCited in: History and Physical Examination - [113]
Avorio F, Russelli G, Alduino R et al.. “Early-Onset Seizures After Orthotopic Liver Transplantation: A Single-Center Retrospective Study.” Transplantation proceedings (2025). PMID: 39824671 ↗
L2bCOHORTCited in: History and Physical Examination, Supportive Care and Complication Management - [114]
Macháček M, Bébarová M. “Triggers of highly lethal seizures induced by novel stimulants: A systematic review focused on synthetic cathinones and phenethylamines.” Neurotoxicology (2026). PMID: 41544778 ↗
L2aSR_OBSCited in: History and Physical Examination, Supportive Care and Complication Management - [115]
You L, Hu M, Li J et al.. “The mechanism of electroacupuncture treatment for post-stroke spasticity: A systematic review and Meta-analysis.” Behavioural brain research (2026). PMID: 41101592 ↗
L2aSR_OBSCited in: History and Physical Examination, Medical Management - [116]
Nail J, Herendeen J. “Postoperative Considerations Following Decompressive Hemicraniectomy.” Neurosurgery clinics of North America (2026). PMID: 41967895 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination, Surgical Management - [117]
Kang K, Ji Z, Hao Y et al.. “Decreased 24-hour Parasympathetic Activity following Intracerebral Hemorrhage: A Key Factor Correlated with Adverse Perihematomal Edema and Poor Functional Outcomes.” CNS neuroscience & therapeutics (2026). PMID: 41499465 ↗
L5OTHERCited in: History and Physical Examination - [118]
Lim MS, AlBaram R, Leonard A et al.. “Electrode Tract Oedema in Stereo-Electroencephalography.” Stereotactic and functional neurosurgery (2026). PMID: 40675143 ↗
L5OTHERCited in: History and Physical Examination, Surgical Management - [119]
Wu T, Wang K, Sun B et al.. “An Implantable System Design Based on Neuromorphic Memristor for Post-Craniotomy Intracranial Pressure Monitoring.” ACS applied materials & interfaces (2025). PMID: 41032885 ↗
L5OTHERCited in: History and Physical Examination, Diagnosis and Workup, Surgical Management - [120]
Nimmo A, Younsi A. “The Relationship Between Inflammation and the Development of Cerebral Ischaemia and Hypoxia in Traumatic Brain Injury-A Narrative Review.” International journal of molecular sciences (2025). PMID: 40869387 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [121]
McClelland AC, Ellis CA, Kuo E et al.. “Atypical Edema in Posterior Reversible Encephalopathy Syndrome: Clinical Associations and Outcome.” Journal of neuroimaging : official journal of the American Society of Neuroimaging (2025). PMID: 40824279 ↗
L5OTHERCited in: History and Physical Examination, Differential Diagnosis - [122]
Pansell J, Thomsson T, Eng E et al.. “Optic Nerve Sheath Diameter: Which Axis Should Be Measured?” Journal of neuroimaging : official journal of the American Society of Neuroimaging (2025). PMID: 40754891 ↗
L5OTHERCited in: History and Physical Examination - [123]
Wang Z, Kulpanowski AM, Copen WA et al.. “Automated detection of severe cerebral edema using explainable deep transfer learning after hypoxic ischemic brain injury.” Resuscitation (2025). PMID: 40414341 ↗
L5OTHERCited in: History and Physical Examination - [124]
Trovato FM, Khan PA, Calvert S et al.. “Cerebral Edema in Acute Liver Failure: Insights From Autopsy.” Liver international : official journal of the International Association for the Study of the Liver (2025). PMID: 40265956 ↗
L5OTHERCited in: History and Physical Examination - [125]
Li Z, Zhang J, Zhang X et al.. “Oxygen metabolism abnormalities and high-altitude cerebral edema.” Frontiers in immunology (2025). PMID: 40176814 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination, Special Populations - [126]
Berra LV, Rubiano A, Cedrone G et al.. “Comparison of brain volume increase in patients with intracranial hypertension after decompressive craniectomy and expansion craniotomy.” Neurosurgical review (2025). PMID: 40113631 ↗
L5OTHERCited in: History and Physical Examination, Surgical Management - [127]
Chen DF, Farrque M, Karakis I et al.. “Continuous Electroencephalography in Acute Liver Failure: Findings and Prognostic Value.” Neurocritical care (2025). PMID: 39920548 ↗
L5OTHERCited in: History and Physical Examination, Supportive Care and Complication Management - [128]
Li H, Wang Y, Li L et al.. “Clinical characteristics, imaging, treatment, and prognosis of dural arteriovenous fistula presented with Parkinsonism- a systematic review.” Neurosurgical review (2025). PMID: 40875094 ↗
L2aSR_OBSCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [129]
Polymeris AA, Lioutas VA, Incontri D et al.. “Evolution of Perihematomal Edema Mean Hounsfield Unit and Its Association with Clinical Outcome in Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial.” Neurocritical care (2025). PMID: 40789806 ↗
L1bRCTCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [130]
Wang L, Wu G, Cao A et al.. “Effect of APOE ε4 Gene on Perihematomal Edema in Intracerebral Hemorrhage: A Prospective Study.” Neurocritical care (2025). PMID: 40764846 ↗
L2bCOHORTCited in: Diagnosis and Workup - [131]
Cardoso FS, Lee WM, Karvellas CJ. “Brain CT Scan Diagnostic and Prognostic Value in Patients With Acute Liver Failure and Cerebral Edema: A Multicenter Cohort Study.” Critical care explorations (2025). PMID: 40232229 ↗
L2bCOHORTCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [132]
Chong ST, Yang JY, Lin CP. “Understanding tractography in edematous brain regions: challenges and solutions.” Brain structure & function (2025). PMID: 40343560 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [133]
Johnson C, Miller G, Shah S et al.. “Unveiling patterns of peri-lead edema after deep brain stimulation: a retrospective review of clinical and demographic factors.” Neuroradiology (2025). PMID: 40198366 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [134]
Guo Y, Hao H, Sun Y. “Generalized cortical encephalitis in autoimmune GFAP astrocytopathy.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40588684 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [135]
Greene JP, Sigman EJ, Podell J et al.. “The Role of Neuroimaging in Traumatic Brain and Spinal Cord Injury.” Seminars in neurology (2025). PMID: 41119962 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [136]
Jiang X, Guo H, Xiao W et al.. “Advancements in Non-Invasive Intracranial Pressure Monitoring via Optic Nerve Sheath Diameter Measurement.” Medical science monitor : international medical journal of experimental and clinical research (2025). PMID: 40413578 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup - [137]
Zou M, Li J, Yao H et al.. “Toxic encephalopathy due to mercury: A rare case report and literature review.” Medicine (2025). PMID: 40958342 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [138]
Jlailati A, Al Sbenaty G, Boali O et al.. “Radiation-induced temporal lobe necrosis in a nasopharyngeal cancer patient after external beam radiotherapy: a case report and review of literature.” Journal of medical case reports (2025). PMID: 40652209 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [139]
Yu Q, Kothe K, Kwiatek RA et al.. “Evidence of White Matter Neuroinflammation in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Diffusion-Based Neuroinflammation Imaging Study.” Human brain mapping (2026). PMID: 41834684 ↗
L5OTHERCited in: Diagnosis and Workup - [140]
Wilting FNH, Douwes JPJ, Patel A et al.. “Deep learning-based automated segmentation of intracerebral haemorrhage, intraventricular haemorrhage and perihaematomal oedema on non-contrast CT.” European stroke journal (2026). PMID: 41792040 ↗
L5OTHERCited in: Diagnosis and Workup - [141]
Basaran AE, Braune M, Barrantes-Freer A et al.. “FOXC1 expression and radiological predictors of peritumoral brain edema in meningiomas.” Journal of neuro-oncology (2026). PMID: 41632362 ↗
L5OTHERCited in: Diagnosis and Workup, Prognosis and Long-term Outcomes - [142]
Remore LG, Fiore G, Pirola E et al.. “Perilead Edema in Deep Brain Stimulation: Long-Term Outcomes and Etiologic Correlates.” Neuromodulation : journal of the International Neuromodulation Society (2026). PMID: 41165632 ↗
L5OTHERCited in: Diagnosis and Workup, Medical Management - [143]
Ding N, Xiang B, Jiang H et al.. “OCT-PAM dual-mode imaging to evaluate early ischemic stroke in rats.” Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2026). PMID: 40832974 ↗
L5OTHERCited in: Diagnosis and Workup - [144]
Carroll D, Darling A, Shrum A et al.. “A Case of Pediatric Opioid Use-Associated Neurotoxicity with Cerebellar Edema (POUNCE) Syndrome Requiring Suboccipital Craniectomy with a Favorable Neurological Outcome.” The Journal of emergency medicine (2026). PMID: 41270319 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [145]
Leon G, Halgas B, Sullivan S et al.. “Frontal Lobe Thermal Injury Mimicking Cerebritis on Imaging.” Journal of burn care & research : official publication of the American Burn Association (2026). PMID: 41172149 ↗
L4CASE_REPORTCited in: Diagnosis and Workup, Differential Diagnosis - [146]
Nagels N, Ghesquière M, Claeys T et al.. “Pseudohypoxic brain swelling in a case of acute craniospinal hypotension.” Acta neurologica Belgica (2026). PMID: 41138028 ↗
L4CASE_REPORTCited in: Diagnosis and Workup - [147]
Garcia-Garcia S, Laajava J, Takala J et al.. “MRI radiomic signature predicts peritumoral brain edema resolution following meningioma surgery.” Acta neurochirurgica (2025). PMID: 41339597 ↗
L5OTHERCited in: Diagnosis and Workup - [148]
He J, Cheng Y, Pan Y et al.. “Comparison of multiple tractography pipelines for corticospinal tract reconstruction applied to brain tumor patients.” Neuroradiology (2025). PMID: 41160112 ↗
L5OTHERCited in: Diagnosis and Workup - [149]
El-Abtah ME, Murayi R, Lee J et al.. “Radiological Differentiation Between Intracranial Meningioma and Solitary Fibrous Tumor/Hemangiopericytoma: A Systematic Literature Review.” World neurosurgery (2023). PMID: 36403933 ↗
L2aSR_OBSCited in: Differential Diagnosis - [150]
Chaudhuri J, Basu S, Roy MK et al.. “Posterior Reversible Leucoencephalopathy Syndrome: Case Series, Comments, and Diagnostic Dilemma.” Current neurology and neuroscience reports (2023). PMID: 37378723 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Supportive Care and Complication Management - [151]
Zouari R, Saeid MZ, Marzouk M et al.. “Diffuse cerebral edema with leukoencephalopathy revealing systemic lupus erythematosus: A case report and review of literature.” Lupus (2023). PMID: 37887528 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [152]
Perillo T, Paolella C, Perrotta G et al.. “Reversible cerebral vasoconstriction syndrome: review of neuroimaging findings.” La Radiologia medica (2022). PMID: 35932443 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [153]
Trivedi S, Chakravarty A. “Neurological Complications of Malaria.” Current neurology and neuroscience reports (2022). PMID: 35699901 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [154]
Guarnizo A, Albreiki D, Cruz JP et al.. “Papilledema: A Review of the Pathophysiology, Imaging Findings, and Mimics.” Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes (2022). PMID: 35044276 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [155]
Fishel Bartal M, Sibai BM. “Eclampsia in the 21st century.” American journal of obstetrics and gynecology (2022). PMID: 32980358 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis, Supportive Care and Complication Management - [156]
Yang B, Guo L, Yang X et al.. “The pathogenesis and treatment of posterior reversible encephalopathy syndrome after neuromyelitis optica spectrum disorder: a case report and literature review.” BMC neurology (2022). PMID: 36539740 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [157]
Gewirtz AN, Gao V, Parauda SC et al.. “Posterior Reversible Encephalopathy Syndrome.” Current pain and headache reports (2021). PMID: 33630183 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis, Supportive Care and Complication Management - [158]
Pujari SS, Kulkarni RV, Ojha P et al.. “Acute haemorrhagic leukoencephalitis (AHLE) - our experience and a short review.” Journal of neuroimmunology (2021). PMID: 34739912 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [159]
Majethia P, Mishra S, Rao LP et al.. “NAD(P)HX dehydratase (NAXD) deficiency due to a novel biallelic missense variant and review of literature.” European journal of medical genetics (2021). PMID: 34161859 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Supportive Care and Complication Management - [160]
Hu S, Yan W, Zhang H et al.. “Acute necrotizing encephalopathy caused by bacterial infection.” BMC infectious diseases (2024). PMID: 39370524 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [161]
Koenigsberg RA, Ross L, Timmerman J et al.. “Case of pediatric cerebellar, hippocampal, and basal nuclei transient edema with restricted diffusion (CHANTER) syndrome in a 2-year-old girl.” Pediatric radiology (2024). PMID: 38630282 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [162]
Fikse DJ, Grenz PM, Wheatley SM et al.. “Posterior reversible encephalopathy syndrome associated with Henoch Schonlein Purpura in a pediatric patient.” The American journal of emergency medicine (2021). PMID: 33097321 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [163]
Theisen A, Bose P, Knight C et al.. “Leukoencephalopathy and cerebral edema as the presenting manifestations of SLE in an ANA-negative adolescent female: a case report and review of literature.” Pediatric rheumatology online journal (2020). PMID: 32660518 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [164]
Dixon L, Varley J, Gontsarova A et al.. “COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia.” Neurology(R) neuroimmunology & neuroinflammation (2020). PMID: 32457227 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [165]
Chionatos RA, Lerner DP, Burns JD et al.. “Alcohol-related posterior reversible encephalopathy syndrome: a case report of a patient managed with a benzodiazepine-sparing regimen for alcohol withdrawal.” Neurocase (2023). PMID: 38700146 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [166]
Parasher A, Jhamb R. “Posterior reversible encephalopathy syndrome (PRES): presentation, diagnosis and treatment.” Postgraduate medical journal (2020). PMID: 32467104 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [167]
Panagopoulos D, Themistocleous M, Apostolopoulou K. “Edema of the Floor of the Fourth Ventricle Accompanying Shunt Malfunction and Disappearance of It After Shunt Repair: Case Report and Literature Review.” The American journal of case reports (2019). PMID: 31874952 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [168]
Brao A, Sánchez Á, Rodríguez I et al.. “Gene therapy rescues brain edema and motor function in a mouse model of megalencephalic leukoencephalopathy with subcortical cysts.” Molecular therapy : the journal of the American Society of Gene Therapy (2025). PMID: 40051162 ↗
L5OTHERCited in: Differential Diagnosis - [169]
Demirel E, Dilek O. “Utilizing Radiomics of Peri-Lesional Edema in T2-FLAIR Subtraction Digital Images to Distinguish High-Grade Glial Tumors From Brain Metastasis.” Journal of magnetic resonance imaging : JMRI (2025). PMID: 39254002 ↗
L5OTHERCited in: Differential Diagnosis - [170]
Dall'Asta A, Melito C, Petrolini C et al.. “First Intrapartum Sonographic Diagnosis of Fetal Hypoxic-Ischemic Encephalopathy.” Fetal diagnosis and therapy (2025). PMID: 39874954 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [171]
Lyu TJ, Wang J, Zhao F et al.. “CCL4 as a potential serum factor in differential diagnosis of central nervous system inflammatory diseases and gliomas.” Frontiers in immunology (2024). PMID: 39364412 ↗
L5OTHERCited in: Differential Diagnosis - [172]
Nada MG, Libda YI, Gohary MM et al.. “Pediatric posterior reversible encephalopathy syndrome: Can MR imaging features predict outcomes in non-oncologic patients?” European journal of radiology (2024). PMID: 38007856 ↗
L5OTHERCited in: Differential Diagnosis - [173]
Czerminski J, Khatri S, Rao B. “Amyloid related imaging abnormalities in the emergency setting.” Emergency radiology (2024). PMID: 39331307 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [174]
Passchier EMJ, Kerst S, Brouwers E et al.. “Aquaporin-4 and GPRC5B: old and new players in controlling brain oedema.” Brain : a journal of neurology (2023). PMID: 37143309 ↗
L5OTHERCited in: Differential Diagnosis - [175]
Ajmi H, Brahim J, Mabrouk S et al.. “Clinical and radiological findings of posterior reversible encephalopathy syndrome in children: About 16 children hospitalized in the pediatric department of a Tunisian tertiary care hospital.” European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society (2023). PMID: 36871341 ↗
L5OTHERCited in: Differential Diagnosis - [176]
Akcil EF, Dilmen OK, Tunali Y. “Hypertonic saline versus mannitol for brain relaxation in supratentorial tumor surgery: a prospective randomized trial.” Brazilian journal of anesthesiology (Elsevier) (2025). PMID: 40967382 ↗
L1bRCTCited in: Medical Management, Surgical Management - [177]
Shi Q, Han S, Li X et al.. “Oxygen Therapy for Intracranial Hemorrhage.” CNS neuroscience & therapeutics (2026). PMID: 41735793 ↗
L2aSR_OBSCited in: Medical Management - [178]
Akhavan-Sigari A, Sbaih O, Hori YS et al.. “Perilesional Edema as a Predictor of Local Failure in Metastatic Brain Lesions Treated With Stereotactic Radiosurgery: A Systematic Review and Meta-Analysis.” International journal of radiation oncology, biology, physics (2026). PMID: 40588068 ↗
L2aSR_OBSCited in: Medical Management, Surgical Management, Prognosis and Long-term Outcomes - [179]
Totapally B, Barhen A, De Angulo G. “Hemorrhagic complications and outcomes of children with acute promyelocytic leukemia at initial hospital admission: a multicenter cohort study.” Pediatric hematology and oncology (2025). PMID: 40384474 ↗
L2bCOHORTCited in: Medical Management - [180]
Tenenbein M. “We need a standardized North American acetylcysteine dosing regimen for the treatment of paracetamol (acetaminophen) poisoning.” Clinical toxicology (Philadelphia, Pa.) (2026). PMID: 41608767 ↗
L5OTHERCited in: Medical Management - [181]
Schutzman LM, Taylor SL, Fiehn O et al.. “Metabolomic Assessment of Low- Versus High-Volume Resuscitation in a Combined Porcine Model of Severe Burn and Traumatic Brain Injury.” Shock (Augusta, Ga.) (2026). PMID: 40997256 ↗
L5OTHERCited in: Medical Management - [182]
Lieschke F, Zheng Y, Lok J et al.. “Dual antiplatelet therapy increases intracerebral hemorrhage and edema after controlled cortical impact and can be partially encountered by 12/15-lipoxygenase inhibition.” Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2026). PMID: 40947949 ↗
L5OTHERCited in: Medical Management - [183]
West E, Patwardhan UM, Calvo R et al.. “Under pressure: Identifying factors for pediatric patients with severe traumatic brain injury who benefit from external ventricular drainage.” Journal of pediatric surgery (2026). PMID: 40803408 ↗
L5OTHERCited in: Medical Management - [184]
Tsuiki N, Aihara T, Hayakawa I et al.. “Child neurology: Early neuroprotective and immunomodulatory intervention in acute shock with encephalopathy and multiorgan failure: Cytokine-storm encephalopathy-case report.” Brain & development (2026). PMID: 41679242 ↗
L4CASE_REPORTCited in: Medical Management - [185]
Alavi Darazam I, Isazadeh M, Zaresharifi S et al.. “Infection With Mycobacterium chelonae Following Autologous Facial Fat Grafting: A Case Report and Review of Literature.” Journal of cosmetic dermatology (2026). PMID: 41449970 ↗
L4CASE_REPORTCited in: Medical Management - [186]
Tian B, Chen M, Cheng J et al.. “Factors and outcomes associated with acute kidney injury in brain tumor resection patients: insights from a large US database (2010-2019).” Renal failure (2025). PMID: 41285121 ↗
L5OTHERCited in: Medical Management - [187]
Liu CC, Chen IW, Liu PH et al.. “Efficacy of propofol-based anesthesia against risk of brain swelling during craniotomy: A meta-analysis of randomized controlled studies.” Journal of clinical anesthesia (2024). PMID: 37883902 ↗
L2aSR_OBSCited in: Surgical Management - [188]
Laajava J, Niemelä M, Korja M. “Peritumoral edema resolves infrequently in surgically treated patients with intracranial meningioma- a retrospective study of 279 meningioma patients.” Journal of neuro-oncology (2025). PMID: 40048039 ↗
L2bCOHORTCited in: Surgical Management - [189]
Tsai CY, Kuo KL, Wu CH et al.. “An Analysis of Emergency Surgical Outcomes for Pediatric Traumatic Brain Injury: A Ten-Year Single-Institute Retrospective Study in Taiwan.” Medicina (Kaunas, Lithuania) (2024). PMID: 39336560 ↗
L2bCOHORTCited in: Surgical Management - [190]
Taussig D, Petrescu AM, Herbrecht A et al.. “Vasogenic oedema during stereoelectroencephalography: intracranial pattern and late-onset clinical repercussion.” Journal of neurology (2024). PMID: 39046522 ↗
L4CASE_REPORTCited in: Surgical Management - [191]
Frost ED, Pruthi A, Tonetti D et al.. “Perihematomal Edema Characteristics After Minimally Invasive Surgery in Intracerebral Hemorrhage.” Critical care explorations (2025). PMID: 41416863 ↗
L5OTHERCited in: Surgical Management - [192]
Ramponi A, Di Cristofori A, Graziano F et al.. “CT hyperdensities after recanalization for anterior circulation large vessels occlusion: a predictor for malignant brain edema after ischemic stroke?” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40954437 ↗
L5OTHERCited in: Surgical Management - [193]
Sconzo D, Ramirez-Velandia F, Enriquez-Marulanda A et al.. “Reversible edema after radiosurgery for arteriovenous malformations (AVMs): Inflow and outflow imbalance.” Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2025). PMID: 40889337 ↗
L5OTHERCited in: Surgical Management - [194]
Tu J, Shen C, Liu J et al.. “Detection of Microscopic Glioblastoma Infiltration in Peritumoral Edema Using Interactive Deep Learning With DTI Biomarkers: Testing via Stereotactic Biopsy.” Journal of magnetic resonance imaging : JMRI (2025). PMID: 40888617 ↗
L5OTHERCited in: Surgical Management - [195]
Sasame J, Shuto T, Matsunaga S et al.. “Effectiveness of Gamma Knife radiosurgery for recurrent glioblastoma: a 10-year retrospective analysis.” Neurosurgical review (2025). PMID: 40653575 ↗
L5OTHERCited in: Surgical Management - [196]
Fukami S, Nagai K, Nakajima N et al.. “Usefulness and pitfalls of neuroendoscopic tumor biopsy for intracranial malignant lymphoma.” Neurosurgical review (2025). PMID: 40439772 ↗
L5OTHERCited in: Surgical Management - [197]
Upadhyay R, Elguindy ANM, Salts L et al.. “Boswellia Serrata for Cerebral Radiation Necrosis After Radiosurgery for Brain Metastases.” International journal of radiation oncology, biology, physics (2025). PMID: 39993542 ↗
L5OTHERCited in: Surgical Management - [198]
Krafft PR, Tafel I, Khanna A et al.. “Dynamic Craniotomy With Khanna NuCrani Plates as an Alternative to Craniotomy With Fixed Plates in Traumatic Brain Injury.” Neurosurgery (2025). PMID: 39495022 ↗
L5OTHERCited in: Surgical Management - [199]
Cui M, Tang X, Xiong W et al.. “Feasibility Study of Endoscopic Surgery for Spontaneous Intracerebral Hemorrhage with Large Hematoma: a Comparison with Craniotomy Using Propensity Score Matching Analysis.” Neurocritical care (2025). PMID: 39192100 ↗
L5OTHERCited in: Surgical Management - [200]
Ong CJ, Huang Q, Kim ISY et al.. “Association of Dynamic Trajectories of Time-Series Data and Life-Threatening Mass Effect in Large Middle Cerebral Artery Stroke.” Neurocritical care (2025). PMID: 38955931 ↗
L5OTHERCited in: Surgical Management - [201]
Shields LBE, Chariker M, Sieg EP et al.. “Vacuum-assisted closure of the scalp flap following malignant cerebral edema during craniotomy: pediatric case presentations and review of the literature.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2025). PMID: 41165862 ↗
L4CASE_REPORTCited in: Surgical Management - [202]
Tuzi S, Kranawetter B, Mielke D et al.. “Systematic assessment of early brain injury severity at admission with aneurysmal subarachnoid hemorrhage.” Neurosurgical review (2024). PMID: 39514015 ↗
L5OTHERCited in: Surgical Management - [203]
Yavorska M, Tomaciello M, Sciurti A et al.. “Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery.” Journal of neuro-oncology (2024). PMID: 39259411 ↗
L5OTHERCited in: Surgical Management - [204]
Li J, Sun W, Hu S et al.. “The Implication of Photodynamic Therapy Applied to the Level of Tumor Resection on Postoperative Cerebral Edema and Intracranial Pressure Changes in Gliomas.” Lasers in surgery and medicine (2024). PMID: 39256928 ↗
L5OTHERCited in: Surgical Management - [205]
Aboukais R, Devalckeneer A, Boussemart P et al.. “Giant unruptured middle cerebral artery aneurysm revealed by intracranial hypertension: is a systematic decompressive hemicraniotomy mandatory?” Neurosurgical review (2024). PMID: 39117892 ↗
L5OTHERCited in: Surgical Management - [206]
Tuzi S, Kranawetter B, Moerer O et al.. “Influence of cerebrospinal fluid drainage in the first days after aneurysm rupture on the severity of early brain injury following aneurysmal subarachnoid hemorrhage.” Acta neurochirurgica (2024). PMID: 38805034 ↗
L5OTHERCited in: Surgical Management - [207]
Ellens NR, Albert GP, Bender MT et al.. “Trends and predictors of decompressive craniectomy in acute ischemic stroke, 2011-2020.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2024). PMID: 38583545 ↗
L5OTHERCited in: Surgical Management - [208]
Guo W, Xu M, Song X et al.. “Association of Serum Macrophage Migration Inhibitory Factor with 3-Month Poor Outcome and Malignant Cerebral Edema in Patients with Large Hemispheric Infarction.” Neurocritical care (2024). PMID: 38561586 ↗
L5OTHERCited in: Surgical Management - [209]
Özen Olcay H, Emektar E, Çorbacıoğlu ŞK et al.. “A retrospective study of CT scan utilization in the emergency department for patients presenting with seizures.” The American journal of emergency medicine (2024). PMID: 38583342 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [210]
Blank SP, Blank RM, Campbell L. “What Is the Optimal Speed of correction of the Hyperosmolar Hyperglycemic State in Diabetic Ketoacidosis? An Observational Cohort Study of U.S. Intensive Care Patients.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2022). PMID: 35688365 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [211]
Park S. “Emergent Management of Spontaneous Subarachnoid Hemorrhage.” Continuum (Minneapolis, Minn.) (2024). PMID: 38830067 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management, Guidelines and Resources - [212]
Leslie-Mazwi TM. “Neurocritical Care for Patients With Ischemic Stroke.” Continuum (Minneapolis, Minn.) (2024). PMID: 38830065 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [213]
Rondon-Berrios H. “Diagnostic and Therapeutic Strategies to Severe Hyponatremia in the Intensive Care Unit.” Journal of intensive care medicine (2024). PMID: 37822230 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [214]
Qaryouti D, Greene-Chandos D. “Neurocritical Care Aspects of Ischemic Stroke Management.” Critical care clinics (2023). PMID: 36333037 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [215]
Youssef G, Wen PY. “Medical and Neurological Management of Brain Tumor Complications.” Current neurology and neuroscience reports (2021). PMID: 34545509 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [216]
Hernandez S, Kittelty K, Hodgson CL. “Rehabilitating the neurological patient in the ICU: what is important?” Current opinion in critical care (2021). PMID: 33395083 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [217]
Mahendra V, Clark SL, Suresh MS. “Neuropathophysiology of preeclampsia and eclampsia: A review of cerebral hemodynamic principles in hypertensive disorders of pregnancy.” Pregnancy hypertension (2021). PMID: 33310389 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [218]
Tlais D, Fetzko S, Gulati N et al.. “A Toddler With New Seizures, Progressive White Matter Lesions, and Multifocal Microhemorrhages.” Pediatrics (2022). PMID: 36325804 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [219]
Gong P, Karakas C, Morgan B. “Child Neurology: Hemiconvulsion-Hemiplegia-Epilepsy Syndrome in the Setting of COVID-19 Infection and Multisystem Inflammatory Syndrome.” Neurology (2022). PMID: 36008144 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [220]
Fragoso DC, Marx C, Dutra BG et al.. “COVID-19 as a Cause of Acute Neonatal Encephalitis and Cerebral Cytotoxic Edema.” The Pediatric infectious disease journal (2021). PMID: 33902082 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [221]
Walabh P, Karvellas CJ. “What's new in the critical care management of acute liver failure: a focus on global accessibility.” Expert review of gastroenterology & hepatology (2025). PMID: 40883866 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [222]
V Bonm A, Taylor LP. “Management of Neurologic Complications in Patients with Brain and Spine Tumors.” Seminars in neurology (2024). PMID: 38176424 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [223]
Ramos AP, Burneo JG. “Seizures and epilepsy associated with central nervous system tuberculosis.” Seizure (2023). PMID: 36963243 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [224]
Aboul-Nour H, Jumah A, Abdulla H et al.. “Neurological monitoring in ECMO patients: current state of practice, challenges and lessons.” Acta neurologica Belgica (2023). PMID: 36701079 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [225]
Greige T, Tao BS, Dangayach NS et al.. “Cerebral Edema Monitoring and Management Strategies: Results from an International Practice Survey.” Neurocritical care (2025). PMID: 39085504 ↗
L5OTHERCited in: Supportive Care and Complication Management, Guidelines and Resources - [226]
Lin R, Luo R, Yu X et al.. “Depleting parenchymal border macrophages alleviates cerebral edema and neuroinflammation following status epilepticus.” Journal of translational medicine (2024). PMID: 39623451 ↗
L5OTHERCited in: Supportive Care and Complication Management - [227]
Teske N, Teske NC, Greve T et al.. “Perifocal edema is a risk factor for preoperative seizures in patients with meningioma WHO grade 2 and 3.” Acta neurochirurgica (2024). PMID: 38581569 ↗
L5OTHERCited in: Supportive Care and Complication Management - [228]
Nie X, Liu J, Yan B et al.. “Cerebral Edema Progression and Outcomes in Large Infarct Patients Undergoing Endovascular Thrombectomy.” Annals of neurology (2025). PMID: 40065687 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [229]
Sheth KN, Albers GW, Saver JL et al.. “Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.” The Lancet. Neurology (2024). PMID: 39577921 ↗
L1bRCTCited in: Prognosis and Long-term Outcomes, Landmark Trials and Key Evidence - [230]
Réen L, Radman A, Visse E et al.. “Outcome in adult patients with severe TBI, using a management protocol allowing a cerebral perfusion pressure ≤ 60 mmHg - a retrospective study over 10 years.” Acta neurochirurgica (2025). PMID: 41128918 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [231]
Weiss SA, Djureinovic D, Wei W et al.. “Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40048689 ↗
L2bTRIAL_NONRANDOMCited in: Prognosis and Long-term Outcomes - [232]
Ehinger E, Darabi A, Visse E et al.. “Antisecretory factor as add-on treatment for newly diagnosed glioblastoma, IDH wildtype: study protocol for a randomized double-blind placebo-controlled trial.” Trials (2025). PMID: 40083039 ↗
L2bTRIAL_NONRANDOMCited in: Prognosis and Long-term Outcomes - [233]
Cliteur MP, Sondag L, Pegge SAH et al.. “The effect of minimally invasive intracerebral haematoma evacuation on early perihaematomal oedema formation.” European stroke journal (2026). PMID: 41614536 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [234]
Defante MLR, de Souza MM, Mendes BX et al.. “Subcutaneous rapid-acting insulin analogues in mild to moderate diabetic ketoacidosis: A meta-analysis of randomized controlled trials.” Journal of diabetes and its complications (2024). PMID: 39437698 ↗
L1aSR_MA_RCTCited in: Special Populations - [235]
Zhou Y, Ding H, Liang H et al.. “Global research trends and emerging hotspots in acute high altitude illness: a bibliometric analysis and review (1937-2024).” Reviews on environmental health (2025). PMID: 40150970 ↗
L2aSR_OBSCited in: Special Populations - [236]
Luks AM, Beidleman BA, Freer L et al.. “Wilderness Medical Society Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Acute Altitude Illness: 2024 Update.” Wilderness & environmental medicine (2024). PMID: 37833187 ↗
L1cGUIDELINECited in: Special Populations - [237]
da Mota MF, de Amorim MM, Correia MDT et al.. “The optic nerve sheath in hypertensive disorders of pregnancy and perinatal outcomes: a cohort study.” BMC pregnancy and childbirth (2024). PMID: 39375707 ↗
L2bCOHORTCited in: Special Populations - [238]
Small E, Goldberg E, Musi M et al.. “Prochlorperazine maleate versus placebo for the prevention of acute mountain sickness: study protocol for a randomized controlled trial.” Trials (2024). PMID: 39574186 ↗
L2bTRIAL_NONRANDOMCited in: Special Populations - [239]
Zila-Velasque JP, Grados-Espinoza P, Goicochea-Romero PA et al.. “Mountain sickness in altitude inhabitants of Latin America: A systematic review and meta-analysis.” PloS one (2024). PMID: 39316567 ↗
L2aSR_OBSCited in: Special Populations - [240]
Sieben N, Ramanan M. “Research Priorities for Diabetic Ketoacidosis: An Evidence and Gap Mapping Review.” Medical sciences (Basel, Switzerland) (2025). PMID: 40407548 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [241]
Manoharan MM, Montes GC, Acquarone M et al.. “Metabolic theory of preeclampsia: implications for maternal cardiovascular health.” American journal of physiology. Heart and circulatory physiology (2024). PMID: 38968164 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [242]
Gatterer H, Villafuerte FC, Ulrich S et al.. “Altitude illnesses.” Nature reviews. Disease primers (2024). PMID: 38902312 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [243]
Han C, Zheng XX, Zhang WF. “High altitude retinopathy: An overview and new insights.” Travel medicine and infectious disease (2024). PMID: 38295966 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [244]
Shinar S, Chitayat D, Shannon P et al.. “Fetal macrocephaly: Pathophysiology, prenatal diagnosis and management.” Prenatal diagnosis (2023). PMID: 38009873 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [245]
Kumar H, Bhakhri BK, Tyagi V et al.. “Characteristics and clinical relevance of leukocytic response in children with diabetic ketoacidosis - A comparative cohort study.” Archives of endocrinology and metabolism (2024). PMID: 39420911 ↗
L2bCOHORTCited in: Special Populations - [246]
Omidi A, Hawley GD, Kain D et al.. “What Is New in Altitude- and Cold-Related Illnesses of Travel: Appraisal and Summary of the Updated Guidelines from the Wilderness Medical Society.” International journal of environmental research and public health (2025). PMID: 40003509 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [247]
Byard RW. “A forensic overview of deaths in mountainous terrain.” Forensic science, medicine, and pathology (2025). PMID: 39503975 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [248]
Leung KKY, Tung JYL, Lee YTK et al.. “A Narrative Review on Diabetic Ketoacidosis in Children.” Current pediatric reviews (2025). PMID: 38299411 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [249]
Derstine M, Jean D, Beidleman BA et al.. “Acute Mountain Sickness and High Altitude Cerebral Edema in Women: A Scoping Review-UIAA Medical Commission Recommendations.” High altitude medicine & biology (2023). PMID: 37870579 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [250]
Ni SY, Wang N, Luo DY et al.. “Discovery of novel salidroside derivatives as potent hypoxia inducible factor 1α (HIF-1α) signaling inhibitors to treat high altitude cerebral edema.” European journal of medicinal chemistry (2025). PMID: 40706447 ↗
L5OTHERCited in: Special Populations - [251]
Fu Q, Qiu R, Tang Q et al.. “Exosomes from high-altitude cerebral edema patients induce cognitive dysfunction by altering oxidative stress responses in mice.” Translational psychiatry (2025). PMID: 40695777 ↗
L5OTHERCited in: Special Populations - [252]
Patel M, Afifi AM, Hercher RL et al.. “Reevaluating bicarbonate therapy in pediatric DKA: A propensity score-matched analysis of neurological and respiratory outcomes.” The American journal of emergency medicine (2025). PMID: 40683034 ↗
L5OTHERCited in: Special Populations - [253]
Lv W, Ma Y, Li D et al.. “Single-Cell RNA Sequencing and Spatial Transcriptomics Reveal a Novel Mechanism of Oligodendrocyte-Neuron Interaction in Cognitive Decline After High-Altitude Cerebral Edema.” CNS neuroscience & therapeutics (2025). PMID: 40546220 ↗
L5OTHERCited in: Special Populations - [254]
DeMayo KM, Havlicek EE, Palumbo J et al.. “Diabetic Ketoacidosis and Venous Thromboembolism: A North American Virtual Pediatric Systems Registry Study, 2014-2023.” Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (2025). PMID: 40439528 ↗
L5OTHERCited in: Special Populations - [255]
Han Y, Li W, Duan H et al.. “Ligustrazine hydrochloride Prevents Ferroptosis by Activating the NRF2 Signaling Pathway in a High-Altitude Cerebral Edema Rat Model.” International journal of molecular sciences (2025). PMID: 39940878 ↗
L5OTHERCited in: Special Populations - [256]
Bergman L, Hannsberger D, Schell S et al.. “Cerebral infarcts, edema, hypoperfusion, and vasospasm in preeclampsia and eclampsia.” American journal of obstetrics and gynecology (2025). PMID: 39486498 ↗
L5OTHERCited in: Special Populations - [257]
Polymeris AA, Lioutas VA, Marchina S et al.. “Hemoglobin and Perihematomal Edema After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial.” Neurocritical care (2026). PMID: 40399657 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [258]
Hernández-Pérez M, Valls-Carbó A, Hernández-Jiménez M et al.. “Changes in Infarct Volume and Cerebral Edema After Mechanical Thrombectomy in Patients With Stroke Randomized to ApTOLL or Placebo: A Secondary Analysis of APRIL Trial.” Stroke (2025). PMID: 40677233 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [259]
Li S, Wang A, Shi L et al.. “Safety and efficacy of Angong Niuhuang Pills in patients with moderate-to-severe acute ischemic stroke (ANGONG TRIAL): A randomized double-blind placebo-controlled pilot clinical trial.” Chinese medical journal (2025). PMID: 39501831 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [260]
Liu X, Zhang X, Fan Y et al.. “Intraoperative goal-directed fluid management and postoperative brain edema in patients having high-grade gliomas resections: a randomized trial.” International journal of surgery (London, England) (2025). PMID: 39037734 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [261]
Huang X, Wang H, Ji Y et al.. “Incidence, predictors, and outcomes of malignant cerebral edema in acute basilar artery occlusion after endovascular treatment: a secondary analysis of the ATTENTION trial.” Journal of neurosurgery (2024). PMID: 38579342 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [262]
Witsch J, Cao Q, Song JW et al.. “Sex Differences in Perihematomal Edema Volume and Outcome After Intracerebral Hemorrhage.” Neurocritical care (2024). PMID: 38379104 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [263]
Sun D, Nguyen TN, Pan Y et al.. “Unsuccessful Recanalization versus Medical Management of Patients with Large Ischemic Core : Analysis of the ANGEL-ASPECT Randomized Trial.” Clinical neuroradiology (2024). PMID: 38319347 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [264]
Feng X, Zhang T, Wang N et al.. “Safety and efficacy of glibenclamide on cerebral oedema following aneurysmal subarachnoid haemorrhage: a randomised, double-blind, placebo-controlled clinical trial.” Stroke and vascular neurology (2024). PMID: 38191184 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [265]
Hayes WN, Laing E, Brown R et al.. “A pragmatic, open-label, randomized controlled trial of Plasma-Lyte-148 versus standard intravenous fluids in children receiving kidney transplants (PLUTO).” Kidney international (2024). PMID: 37914088 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [266]
Zhu X, Han Q, Xia L et al.. “Efficacy of two hemodialyses in patients with chronic renal failure complicated by massive intracerebral hemorrhage.” Annals of clinical and translational neurology (2023). PMID: 37350299 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [267]
Li N, Guo J, Kang K et al.. “Cytotoxic Edema and Adverse Clinical Outcomes in Patients with Intracerebral Hemorrhage.” Neurocritical care (2023). PMID: 36180765 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [268]
Wang J, Xiong X, Zou J et al.. “Combination of Hematoma Volume and Perihematoma Radiomics Analysis on Baseline CT Scan Predicts the Growth of Perihematomal Edema.” Clinical neuroradiology (2023). PMID: 35943522 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [269]
Lee KH, Lioutas VA, Marchina S et al.. “The Prognostic Roles of Perihematomal Edema and Ventricular Size in Patients with Intracerebral Hemorrhage.” Neurocritical care (2022). PMID: 35676589 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [270]
Lombardo S, Smith MC, Semler MW et al.. “Balanced Crystalloid versus Saline in Adults with Traumatic Brain Injury: Secondary Analysis of a Clinical Trial.” Journal of neurotrauma (2022). PMID: 35443809 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [271]
Zhao W, Jiang F, Li S et al.. “Safety and efficacy of remote ischemic conditioning for the treatment of intracerebral hemorrhage: A proof-of-concept randomized controlled trial.” International journal of stroke : official journal of the International Stroke Society (2022). PMID: 33739197 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [272]
Maiwall R, Bajpai M, Singh A et al.. “Standard-Volume Plasma Exchange Improves Outcomes in Patients With Acute Liver Failure: A Randomized Controlled Trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022). PMID: 33524593 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [273]
Lowe SL, Duggan Evans C, Shcherbinin S et al.. “Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.” The journal of prevention of Alzheimer's disease (2021). PMID: 34585215 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [274]
Ng FC, Churilov L, Yassi N et al.. “Association between pre-treatment perfusion profile and cerebral edema after reperfusion therapies in ischemic stroke.” Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2021). PMID: 33993795 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [275]
Scheldeman L, Wouters A, Dupont P et al.. “Reversible Edema in the Penumbra Correlates With Severity of Hypoperfusion.” Stroke (2021). PMID: 33980046 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [276]
Mintun MA, Lo AC, Duggan Evans C et al.. “Donanemab in Early Alzheimer's Disease.” The New England journal of medicine (2021). PMID: 33720637 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [277]
Leasure AC, Kuohn LR, Vanent KN et al.. “Association of Serum IL-6 (Interleukin 6) With Functional Outcome After Intracerebral Hemorrhage.” Stroke (2021). PMID: 33682454 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [278]
Zusman BE, Kochanek PM, Bell MJ et al.. “Cerebrospinal Fluid Sulfonylurea Receptor-1 is Associated with Intracranial Pressure and Outcome after Pediatric TBI: An Exploratory Analysis of the Cool Kids Trial.” Journal of neurotrauma (2021). PMID: 33430695 ↗
L1bRCTCited in: Landmark Trials and Key Evidence - [279]
Cook AM, Morgan Jones G, Hawryluk GWJ et al.. “Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients.” Neurocritical care (2020). PMID: 32227294 ↗
L1cGUIDELINECited in: Guidelines and Resources - [280]
Ghannoum M, Laliberté M, Nolin TD et al.. “Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup.” Clinical toxicology (Philadelphia, Pa.) (2015). PMID: 25950372 ↗
L1cGUIDELINECited in: Guidelines and Resources - [281]
Spasovski G, Vanholder R, Allolio B et al.. “Clinical practice guideline on diagnosis and treatment of hyponatraemia.” European journal of endocrinology (2014). PMID: 24569125 ↗
L1cGUIDELINECited in: Guidelines and Resources - [282]
Spasovski G, Vanholder R, Allolio B et al.. “Clinical practice guideline on diagnosis and treatment of hyponatraemia.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2014). PMID: 24569496 ↗
L1cGUIDELINECited in: Guidelines and Resources - [283]
Wijdicks EF, Sheth KN, Carter BS et al.. “Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association.” Stroke (2014). PMID: 24481970 ↗
L1cGUIDELINECited in: Guidelines and Resources - [284]
Stravitz RT, Kramer AH, Davern T et al.. “Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group.” Critical care medicine (2007). PMID: 17901832 ↗
L1cGUIDELINECited in: Guidelines and Resources - [285]
Soffietti R, Cornu P, Delattre JY et al.. “EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force.” European journal of neurology (2006). PMID: 16834697 ↗
L1cGUIDELINECited in: Guidelines and Resources - [286]
Vahedi K, Proust F, Geeraerts T. “[Experts' recommendations for stroke management in intensive care: intracranial hypertension].” Revue neurologique (2012). PMID: 22571966 ↗
L1cGUIDELINECited in: Guidelines and Resources - [287]
Luks AM, Auerbach PS, Freer L et al.. “Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019 Update.” Wilderness & environmental medicine (2019). PMID: 31248818 ↗
L1cGUIDELINECited in: Guidelines and Resources - [288]
Luks AM, McIntosh SE, Grissom CK et al.. “Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update.” Wilderness & environmental medicine (2014). PMID: 25498261 ↗
L1cGUIDELINECited in: Guidelines and Resources - [289]
Bennett BL, Hew-Butler T, Hoffman MD et al.. “Wilderness Medical Society practice guidelines for treatment of exercise-associated hyponatremia.” Wilderness & environmental medicine (2013). PMID: 23590928 ↗
L1cGUIDELINECited in: Guidelines and Resources - [290]
Luks AM, McIntosh SE, Grissom CK et al.. “Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness.” Wilderness & environmental medicine (2010). PMID: 20591379 ↗
L1cGUIDELINECited in: Guidelines and Resources - [291]
Liao KH, Chang CK, Chang HC et al.. “Clinical practice guidelines in severe traumatic brain injury in Taiwan.” Surgical neurology (2009). PMID: 19818476 ↗
L1cGUIDELINECited in: Guidelines and Resources - [292]
Prasad GL, Pai A, Pt S. “Short course of low-dose steroids for management of delayed pericontusional edema after mild traumatic brain injury - A retrospective study.” Surgical neurology international (2025). PMID: 39926471 ↗
L2bCOHORTCited in: Guidelines and Resources - [293]
Rapp A, Kobeissi H, Fahim DK. “Updated Review of the Management of and Guidelines for Traumatic Brain Injury.” Journal of clinical medicine (2025). PMID: 41095876 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [294]
Suarez JI. “Diagnosis and Management of Subarachnoid Hemorrhage.” Continuum (Minneapolis, Minn.) (2015). PMID: 26426230 ↗
L5REVIEW_NARRATIVECited in: Guidelines and Resources - [295]
McBride DW, Szu JI, Hale C et al.. “Reduction of cerebral edema after traumatic brain injury using an osmotic transport device.” Journal of neurotrauma (2014). PMID: 24959845 ↗
L5OTHERCited in: Guidelines and Resources - [296]
Hays AN, Lazaridis C, Neyens R et al.. “Osmotherapy: use among neurointensivists.” Neurocritical care (2011). PMID: 21153930 ↗
L5OTHERCited in: Guidelines and Resources - [297]
Zusman BE, Kochanek PM, Jha RM. “Cerebral Edema in Traumatic Brain Injury: a Historical Framework for Current Therapy.” Current treatment options in neurology (2020). PMID: 34177248 ↗
L5OTHERCited in: Guidelines and Resources - [298]
Schur S, Martel P, Marcoux J. “Optimal Bone Flap Size for Decompressive Craniectomy for Refractory Increased Intracranial Pressure in Traumatic Brain Injury: Taking the Patient's Head Size into Account.” World neurosurgery (2020). PMID: 32035212 ↗
L5OTHERCited in: Guidelines and Resources